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Résumé 
 
Introduction: Les efforts globaux pour contrôler la tuberculose sont présentement restreints 
par la prévalence croissante du VIH/SIDA. Quoique les éclosions de la tuberculose multi 
résistante (TB-MDR) soient fréquemment rapportées parmi les populations atteintes du 
SIDA, le lien entre VIH/SIDA et le développement de résistance n’est pas clair. 
 
Objectifs: Cette recherche visait à : (1) développer une base de connaissances concernant les 
facteurs associés à des éclosions de la TB-MDR parmi les patients atteints du VIH/SIDA; (2) 
utiliser ce cadre de connaissances pour accroître des mesures préliminaires pour mieux 
contrôler la tuberculose pulmonaire chez les patients atteints du VIH/SIDA; et (3) afin 
d’améliorer l’application des ces mesures, affiner les techniques bactériologiques existantes 
pour Mycobacterium tuberculosis. 
 
Méthodologie: Quatre études ont été réalisées : (1) Une étude longitudinale pour 
identifier les facteurs associés avec une éclosion de la TB-MDR parmi les patients atteints du 
SIDA qui ont reçu le traitement directement supervisé de courte durée (DOTS) pour la 
tuberculose pulmonaire au Lima et au Pérou entre 1999 et 2005; (2) Une étude transversale 
pour décrire différentes étapes de l’histoire naturelle de la tuberculose, la prévalence et les 
facteurs associés avec la mycobactérie qu’on retrouve dans les selles des patients atteints du 
SIDA; (3) Un projet pilote pour développer des stratégies de dépistage pour la tuberculose 
pulmonaire parmi les patients hospitalisés atteints du SIDA, en utilisant l’essaie Microscopic 
Observation Drug Susceptibility (MODS); et (4) Une étude laboratoire pour identifier les 
meilleures concentrations critiques pour détecter les souches MDR de M. tuberculosis en 
utilisant l’essaie MODS. 
 
Résultats : Étude 1 démontre qu’une épidémie de TB-MDR parmi les patients atteints du 
SIDA qui ont reçu DOTS pour la tuberculose pulmonaire ait été causée par la superinfection 
du clone de M. tuberculosis plutôt que le développement de la résistance secondaire. Bien 
iv 
 
 
que ce clone ait été plus commun parmi la cohorte de patients atteints du SIDA, il n’avait 
aucune différence de risque pour superinfection entre les patients avec ou sans SIDA. Ces 
résultats suggèrent qu’un autre facteur, possiblement associé à la diarrhée, peu contribuer à la 
prévalence élevée de ce clone chez les patients atteints du SIDA. Étude 2 suggère que chez la 
plupart des patients atteints du SIDA il a été retrouvé une mycobactérie dans leurs selles 
alors qu’ils étaient en phase terminale au niveau  de la tuberculose pulmonaire. Or, les 
patients atteints du SIDA ayant été hospitalisés pendant les deux dernières années pour une 
autre condition médicale sont moins à risque de se retrouver avec une mycobactérie dans 
leurs selles. Étude 3 confirme que la tuberculose pulmonaire a été commune à tous les 
patients hospitalisés atteints du SIDA, mais diagnostiquée incorrectement en utilisant les 
critères cliniques présentement recommandés pour la tuberculose. Or, l’essaie MODS a 
détecté pour la plupart de ces cas. De plus, MODS a été également efficace quand la méthode 
a été dirigée aux patients soupçonnés d’avoir la tuberculose, à cause de leurs symptômes. 
Étude 4 démontre les difficultés de détecter les souches de M. tuberculosis avec une faible 
résistance contre ethambutol et streptomycine en utilisant l’essai MODS avec les 
concentrations de drogue présentement recommandées pour un milieu de culture. Cependant, 
l’utilité diagnostique de MODS peut être améliorée ; modifier les concentrations critiques et 
utiliser deux plaques et non une, pour des tests réguliers. 
 
Conclusion: Nos études soulèvent la nécessité d’améliorer le diagnostic et le traitement de la 
tuberculose parmi les patients atteints du SIDA, en particulier ceux qui vivent dans des 
régions avec moins de ressources. Par ailleurs, nos résultats font ressortir les effets indirects 
que les soins de santé ont sur les patients infectés par le VIH et qu’ils peuvent avoir sur le 
développement de la tuberculose. 
 
Mots clés: La tuberculose pulmonaire ; VIH/SIDA ; la tuberculose multi résistante ; l’essaie 
Microscopic Observation Drug-Susceptibility 
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Summary 
 
Background: Global efforts to control tuberculosis are currently being hampered by a 
continuing rise in the prevalence of HIV/AIDS. Although outbreaks of multidrug resistant 
tuberculosis (MDR-TB) are commonly reported among AIDS populations, the link between 
HIV/AIDS and the development of drug-resistance remains unclear. 
 
Objectives: This thesis aimed to: (1) build a knowledge foundation regarding underlying 
factors associated with outbreaks of MDR-TB among HIV/AIDS patients; (2) use this 
knowledge framework to develop preliminary health measures for controlling pulmonary 
tuberculosis among HIV/AIDS patients; and (3) in an effort to better implement these health 
measures, refine existing culture-based diagnostics for Mycobacterium tuberculosis. 
 
Methods: Four studies were conducted: (1) a longitudinal study to identify the underlying 
factors associated with an epidemic of MDR-TB among AIDS patients receiving Directly-
Observed Therapy Short-course (DOTS) for pulmonary tuberculosis in Lima, Peru between 
1999 and 2005; (2) a cross-sectional study to characterize the prevalence and factors 
associated with gastrointestinal shedding with mycobacteria among AIDS patients at 
different stages in the natural history of tuberculosis; (3) a pilot study to develop screening 
strategies for pulmonary tuberculosis among hospitalized HIV/AIDS patients using the 
Microscopic Observation Drug Susceptibility (MODS) assay; and (4) a laboratory-based 
study to define the optimal critical concentrations needed for detecting drug resistance in M. 
tuberculosis using MODS. 
 
Results: Study 1 revealed that an epidemic of MDR-TB among AIDS patients receiving 
DOTS for pulmonary tuberculosis was due to super-infection with a specific clone of M. 
tuberculosis rather than the development of secondary drug-resistance. Although this 
epidemic clone was more common among patients in the AIDS cohort, risk of super-
infection did not differ between AIDS and non-AIDS patients after adjusting for baseline risk 
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of exposure, suggesting that another factor possibly associated with diarrhea may be 
contributing to the strain’s high prevalence among AIDS patients. Study 2 showed that the 
majority of AIDS patients in the later stages of pulmonary tuberculosis exhibited 
gastrointestinal shedding with mycobacteria. Stool shedding was rare in the absence of 
pulmonary tuberculosis. AIDS patients were also less likely to shed mycobacteria if they had 
been hospitalized during the previous two years for another medical condition. Study 3 
confirmed that pulmonary tuberculosis was common among hospitalized AIDS patients but 
frequently misdiagnosed using currently recommended diagnostic algorithms. The MODS 
assay detected most cases and was equally effective when targeted to patients clinically 
suspicious for tuberculosis. Study 4 demonstrated that low grade drug resistance in M. 
tuberculosis to ethambutol and streptomycin was difficult to detect with MODS using 
currently recommended drug-concentration standards in broth. Its diagnostic utility could be 
improved by modifying drug-concentration standards, and including two versus one critical 
concentration well for standardized testing.  
 
Conclusion: Our studies underscore the need to improve the diagnosis and treatment of 
tuberculosis among AIDS patients living in resource-constrained settings, all in an effort to 
prevent morbidity, mortality and the transmission of drug-resistant strains. They also 
highlight the indirect effect that general health care among HIV-infected patients can have on 
the development of tuberculosis. 
 
Keywords: Pulmonary tuberculosis; HIV/AIDS; Multi-drug resistance; Gastrointestinal 
shedding; Microscopic Observation Drug Susceptibility assay  
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Preface 
 
The first three studies in this thesis were based on existing larger cohort studies conducted in 
Lima, Peru between 1999 and 2005 and aimed at: 
 
 Evaluating the validity of different diagnostic methods for Mycobacterium 
tuberculosis. 
 Studying the longitudinal effects of HIV and multidrug resistance on time to culture 
conversion and mortality during Directly Observed Treatment, Short-course for 
tuberculosis. 
 
In this regard, the first three studies of this thesis represent original attempts to: (1) identify 
the underlying factors associated with an epidemic of multidrug-resistant tuberculosis (MDR-
TB) among AIDS patients in Lima, Peru using molecular data; (2) characterize the 
prevalence and risk factors for mycobacteria stool shedding among AIDS patients at different 
stages in the natural history of tuberculosis; and (3) evaluate the utility of targeted versus 
blanket screening of HIV-infected patients with the Microscopic Observation Drug 
Susceptibility (MODS) assay. The strength of the first two studies lies not only in the topic 
selected but in the way we analyzed the data, using both cohort and individual-level 
differences in order to study these phenomena.  For the third study in this thesis, our research 
represented the first to take into consideration the clinical context of diagnosis when 
evaluating the utility of MODS. 
While the datasets used for all three studies were not originally designed to answer 
any of these research questions, careful examination of the study protocols and data 
collection sheets revealed that they could be used to answer the research questions proposed 
for this thesis. Following this decision, datasets were cleaned, missing data was retrieved and 
all RFLP gels and spoligotype results were re-analyzed It should be noted that new data 
collection for the first study would not have possible today, given that the epidemic of MDR-
TB has now subsided. 
The final study in this thesis represents completely original work. During my initial 
research on the Microscopic Observation Drug Susceptibility assay (prior to the initiation of 
xxi 
 
 
the PhD), it became apparent that critical concentrations for this test had never been 
evaluated for multiple drugs across a range of concentrations. This research gap propelled me 
to begin designing and conducting experiments in this area. Part of this research (i.e., for two 
of the drugs) is presented in Chapter 7 of this thesis. 
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CHAPTER 1.  
 Introduction 
 
Tuberculosis remains a major cause of morbidity and mortality 1-3. In 2006, the World Health 
Organization (WHO) identified 9.2 million new cases and 1.7 million deaths from 
tuberculosis 1. Although public health efforts to control tuberculosis since the mid 1990’s, 
have helped to stem the global incidence of this disease, in more recent years, there has been 
growing concerns regarding a steady rise in the incidence of tuberculosis in regions with a 
high prevalence of HIV/AIDS 1. The link between tuberculosis and HIV/AIDS has been 
particularly evident in Africa, which not only experiences the highest rates of tuberculosis in 
the world (363 cases per 100 000 in Africa versus 139 cases per 100 000 in the world) but 
also accounts for 85 percent of the world’s cases of AIDS-associated tuberculosis 1,4.  
Tuberculosis remains the single most common cause of morbidity and mortality from 
opportunistic infections among AIDS patients 5. Of 33 million people who are currently 
infected with HIV/AIDS and 2 million people who die from AIDS each year, 700 000 cases 
and 200 000 deaths are attributable to tuberculosis 5 1. The WHO has also noted that in sub-
regions of Africa where the prevalence of HIV infection is high, changes in the incidence of 
tuberculosis are directly proportional to fluctuations in the prevalence of HIV 1. 
Part of this problem is due to HIV-infected patients being not only at greater risk of 
infection with tuberculosis, but also of progressing from latent to active stages of the disease, 
once infected with the tubercle bacilli 6. Of the one-third of the world’s population who are 
currently infected with Mycobacterium tuberculosis (the main causative agent of tuberculosis 
disease) 2, between five to ten percent of tuberculosis-infected individuals will develop active 
forms of the disease during their lifetime 4,6. This number increases to 50 percent when 
patients are co-infected with HIV 4,6.  
Further complicating worldwide efforts to control tuberculosis are significant geo-
economic differences in disease burden. Aside from affecting the most economically 
productive age groups of society (75 percent of active tuberculosis cases occur among 
patients between 15 and 50 years of age 6), 95 percent of new tuberculosis cases and 98 
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percent of deaths due to tuberculosis occur in developing countries where health resources to 
control the disease are often limited 7.  
Amidst this health crisis, reports of ongoing outbreaks of multi drug-resistant TB 
(MDR-TB) and extensively drug-resistant TB (XDR-TB) among hospitalized AIDS patients 
and prison populations with a high prevalence of HIV have also led to concerns regarding a 
potential link between AIDS and the development of drug-resistant tuberculosis. Published 
studies on hospital outbreaks of MDR-TB frequently cite delays in the diagnosis and 
treatment of tuberculosis, an increased likelihood of defaulting from treatment among AIDS 
patients, and poor infection control measures as key contributing factors to these public 
health events 8,9. However, epidemiological studies have rarely identified a link between 
MDR-TB and AIDS during non-outbreak periods of time, making it unclear whether an 
association actually exists.   
 
In this context, the purpose of this thesis was to:  
(1) Build a knowledge foundation regarding underlying factors associated with an 
outbreak of MDR-TB among HIV/AIDS patients;  
(2) Use this knowledge framework to develop preliminary health measures for 
controlling pulmonary tuberculosis among HIV/AIDS patients; and  
(3) Refine existing culture-based diagnostics for Mycobacterium tuberculosis, in an 
effort to better implement these health measures. 
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CHAPTER 2.  
 Review of the Literature 
 
2.1. Biomedical Framework for Tuberculosis Control 
Most public health efforts to contain tuberculosis center on interrupting person-to-person 
transmission of M. tuberculosis. While the tubercle bacillus was first identified by Robert 
Koch in 1882, its mode of transmission was not formally established until the 1960’s, when it 
was shown that M. tuberculosis could be transmitted through aerosolized droplet nuclei 10. 
Since then, much of the scientific literature on transmission dynamics has focused on 
elucidating the biophysical processes which enable dissemination of tuberculosis to occur 11.  
Person-to-person transmission of M. tuberculosis takes place when the tubercle bacilli 
are spread through respiratory droplets from a contagious person to a susceptible host. At the 
patient-level, the probability of transmission will depend on the manner in which the infector 
releases M. tuberculosis (e.g., talking, coughing or sneezing), and the extent to which an 
infector is ill at the time of transmission (e.g., cavitation in the lung or positive smear status). 
Once M. tuberculosis is released into the air, the probability that the microorganism will 
survive depends not only the innate viability of the bacteria to survive but also on 
environmental stressors which the bacteria is exposed to (e.g., ambient temperature, presence 
of ultraviolet rays or level of humidity) and size of aerosolized droplets. If the tubercle bacilli 
are able to survive this transmission process, the probability that a person will be infected 
will then depend on their level of immunological resistance towards the microorganism (e.g., 
genetic factors or HIV/AIDS). A person who becomes infected may then enter one of two 
stages of tuberculosis disease: a dormant asymptomatic phase or an active symptomatic 
phase. When patients with active pulmonary tuberculosis release M. tuberculosis into the 
environment, the entire tuberculosis transmission cycle is reinitiated.  
At the community-level, the risk of transmitting M. tuberculosis will depend on the 
number of cases capable of transmitting the mycobacterium, the duration of infectiousness 
for each case, as well as the number and/or duration of encounters between the source of 
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infection and susceptible individuals 12. All of these factors are influenced by how rapidly 
case detection and treatment of an infected individual occurs.  
The classic biomedical model for controlling communicable diseases focuses on 
interrupting person-to-person transmission through one of three stages of the disease (figure 
2.1), namely the diagnostic, treatment, and preventive phases. It is within this disease-
centered framework that the Directly Observed Treatment, Short-Course (DOTS)  strategy 
for tuberculosis control was developed 13. The program is based on five pillars. They include: 
[1] Political commitment to combating tuberculosis, [2] Case detection using quality-assured 
bacteriology, [3] Standardized treatment for tuberculosis during at least five months with 
supervision and patient support, [4] Regular supply of anti-tubercular drugs, and [5] 
Standardized monitoring and surveillance of treatment results 14.  
 
 
 
Figure 2.1. Biomedical framework for tuberculosis control 
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2.1.1. Diagnostic Stage 
The first critical element in transmission control efforts has been the proper diagnosis of 
tuberculosis 15. The International Standards for Tuberculosis Care currently recommend that 
any patient with otherwise unexplained productive cough for more than two to three weeks; 
or, chest radiographic findings suggestive of tuberculosis, be asked to provide sputum 
samples for bacteriological confirmation of pulmonary tuberculosis 16. Appropriate 
specimens should also be collected from patients with clinical manifestations suggestive of 
extra pulmonary tuberculosis 16. 
Although, numerous laboratory tests have been developed to rapidly and accurately 
detect M. tuberculosis in clinical specimens (please refer to Appendix 1), cost and the need 
for complex laboratory facilities often limits their use in resource-constrained settings 17. 
Instead, most laboratory-based diagnosis are made using the Acid Fast Bacilli (AFB) Smear 
Stain, which detects 50 to 60 percent of tuberculosis cases in countries with access to high 
quality microscopy services 18,19. Patients with culture-positive tuberculosis who test negative 
using AFB smear stain are commonly referred to as smear-negative culture-positive cases, 
and remain a key limitation for current tuberculosis control efforts. Immunosuppressed 
individuals with pulmonary tuberculosis may be at particular risk for smear-negative culture-
positive disease since they are less likely to undergo lung cavitation, which increases the 
bacillary load in sputum. AFB smear stain also cannot differentiate between different 
mycobacterium species or determine whether the tubercle bacilli are still viable.  
While Löwenstein-Jensen culture remains a widely available culture-based method of 
detection in low and middle-income countries, the six to eight week delay needed to process 
samples substantially limits its clinical practicality 20,21. Clinical presentation of symptoms, 
radiological findings and other laboratory-based indicators may also be used to identify 
smear-negative patients 21-25. However, co-infection with HIV can make this diagnostic 
process more complex, particularly if patients are immunosuppressed. For example, while 
constitutional symptoms such as weight loss and fever, can be useful markers for tuberculosis 
among HIV-infected patients, a differential diagnosis must also be made between pulmonary 
tuberculosis and other opportunistic pulmonary diseases such as acute bacterial pneumonia, 
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Kaposi sarcoma or Pneumocystis carinii pneumonia 6. Chest radiographic patterns may be 
atypical depending on the extent of patient immunosuppression 6. Tuberculin skin tests may 
also be of limited value in these settings since the test cannot differentiate between the 
infectious and disease forms of tuberculosis or the presence of M. tuberculosis versus other 
environmental mycobacterium. False-negative results are common among patients who are 
immunosuppressed, suffer severe malnutrition or have miliary tuberculosis 26.  
 Similarly, the diagnosis of patients with MDR-TB [i.e., M. tuberculosis that is 
resistant to the two first-line anti-tubercular drugs isoniazid and rifampicin] and XDR-TB 
[i.e. MDR-TB that is also resistant to fluoroquinolone and at least one second-line injectable 
drug, namely amikacin, capreomycin or kanamycin 27] is an essential component to treating 
tuberculosis effectively. The only means of identifying a patient with drug-resistant 
tuberculosis is through either treatment failure or drug-susceptibility testing.  
While the proportion method by agar is often considered the reference standard of 
drug-susceptibility testing, it can take as much as 12 weeks in order to provide results, thus 
increasing morbidity and mortality among patients 28. Although molecular techniques such as 
line probe assays can be used to detect drug-resistance in samples in 1 to 2 days, cost and the 
need for complex laboratory facilities often limits their utility in the developing world 28. The 
diagnostic also has a lower sensitivity for detecting smear-negative samples, and 
transferability of technology for other pathogens can be difficult since it only detects a 
limited number of mutations 28,29.  
On a similar note, while numerous rapid and reliable drug-susceptibility tests exist for 
MDR forms of TB, drug-susceptibility testing for XDR-TB cases continues to be poor, hence 
the use of MDR-TB as a first criteria to define all XDR-TB cases 28. This brings us to the 
second dimension of tuberculosis control: treatment. 
 
2.1.2. Treatment Stage 
Since the discovery of streptomycin for treating pulmonary tuberculosis in 1948, a second 
element for controlling tuberculosis has been the use of antibiotics 30. If active tuberculosis is 
left untreated in otherwise healthy individuals, approximately 50 percent of patients will die, 
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25 percent will develop the chronic form of the disease and 25 percent will become self-
cured 6. While the number of anti-tubercular drugs and length of time needed to treat 
tuberculosis creates significant challenges for treatment compliance (Table 2.1), the DOTS 
program has significantly improved cure rates for the disease through patient support and 
daily monitoring of drug intake 31,32. Within a well-functioning DOTS program, cure rates for 
drug-susceptible tuberculosis now exceed 85 percent 1.  
 
 
Table 2.1. Treatment regimens used for Directly Observed Therapy Short-Course of 
tuberculosis in Peru 
 
 
DOTS Treatment Scheme Two 
(Total of 6 months of treatment – 82 doses) 
 
Phase Duration Frequency Medication & Dose Total Medication 
 
First 2 months 
(50 doses) 
Daily, except 
Sunday and 
holidays 
Rifampicin x 300 mg (2 capsules) 
Isoniazid x 100 mg (3 tablets) 
Pyrazinamide x 500 mg (3 tablets) 
Ethambutol x 400 mg (3 tablets) 
 
Rifampicin x 300 mg = 
164 capsules 
Isoniazid x 100 mg = 
406 tablets 
Pyrazinamide x 500 mg = 
150 tablets 
Ethambutol x 400 mg = 
150 tablets 
Second 4 months 
(32 doses) 
Two doses 
per week 
Rifampicin x 300 mg (2 capsules) 
Isoniazid x 100 mg (8 tablets) 
 
DOTS Treatment Scheme Two 
(Total of 8 months of treatment – 115 doses) 
 
Phase Duration Frequency Medication & Dose Total Medication 
 
 
 
First 
2 months 
(50 doses) 
Daily except Sundays & 
holidays 
Rifampicin x 300 mg (2 capsules) 
Isoniazid x 100 mg (3 tablets) 
Pyrazinamide x 500 mg (3 tablets) 
Ethambutol x 400 mg (3 tablets) 
Streptomycin x 1 g (1 ampoule) 
 
 
 
Rifampicin x 300 mg = 
230 capsules 
Isoniazid x 100 mg = 
545 tablets 
Pyrazinamide x 500 mg 
= 225 tablets 
Ethambutol x 400 mg =  
465 tablets 
Streptomycin x 1 g = 
50 ampoules 
1 month 
(25 doses) 
Daily except Sundays & 
holidays 
Rifampicin x 300 mg (2 capsules) 
Isoniazid x 100 mg (3 tablets) 
Pyrazinamide x 500 mg (3 tablets) 
Ethambutol x 400 mg (3 tablets) 
 
 
Second 
5 months 
(40 doses) 
Twice per week Rifampicin x 300 mg (2 capsules) 
Isoniazid x 100 mg (8 tablets) 
Ethambutol x 400 mg (6 tablets) 
 
 
Source: Mazzetti PS. Norma técnica de salud para el control de la tuberculosis. Ministerio de Salud del 
Perú. Lima: 2006. 
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Notwithstanding these advances, there have been growing concerns in recent years regarding 
the emergence of MDR-TB and XDR-TB, particularly among populations with a high 
prevalence of HIV 4,33. It is estimated that five percent of tuberculosis cases in the world are 
multi-drug resistant, from which seven percent of these cases are XDR forms of the disease 
34. Country rates for MDR-TB range from zero percent in several Western European 
countries to more than 35 percent in some former Soviet Union countries. Forty-five 
countries have reported at least one XDR-TB case since 2002 34. 
 Rapid bacteriological confirmation of drug-susceptibility status and administration of 
appropriate drug-therapy remain the most important determinants for treatment success of  
patients with drug-resistant tuberculosis. Heymann et al. 35 underscore the importance of 
rapid drug-susceptibility testing by predicting that effective use of testing can reduce time to 
diagnosis by 38 percent, time to acceptable therapy by 70 percent and mortality by 31 
percent. Among HIV positive individuals, drug-susceptibility testing is equally effective, 
reducing the time to diagnosis by 39 percent, time to acceptable therapy by 59 percent and 
mortality by 24 percent.  
Despite this evidence, it is estimated that only two percent of the world’s MDR-TB 
cases are currently detected and appropriately treated 36. In many resource-constrained 
settings, selection of drug-therapy is based on the patient’s history of tuberculosis rather than 
bacteriological confirmation of drug-susceptibility status due to cost and complex laboratory 
facilities needed in order to bacteriologically confirm drug-resistance. Until recently, the 
WHO had only advocated testing in resource-constrained settings for patients who failed at 
least five months of initial treatment or a supervised re-treatment regimen 35. Selection of a 
standardized drug-therapy regimen is thus often based on a patient’s treatment history for 
TB. In Peru, for example, Table 2.1 illustrates that DOTS scheme 1 is administered to “never 
treated” patients; and DOTS scheme 2 to “previously treated” patients who interrupted or 
failed treatment 37. Such strategies can not only lead to inappropriate treatment for patients 
infected with drug-resistant tuberculosis for the first time, but also prolong infectivity and the 
further development of drug-resistant tuberculosis. 
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The treatment of tuberculosis among HIV/AIDS patients may be further complicated 
by their increased risk for gastrointestinal malabsorption of anti-tubercular drugs 38-43. Lower 
bioavailability of antibiotics in the bloodstream can increase, in turn, a patient’s risk of 
developing drug-resistance 44. Although the link between HIV-infection and multi-drug 
resistance remains unclear, several observational studies and randomized clinical trials have 
detected a link between HIV status and the development of resistance to rifamycins (the 
family group of rifampicin) 8,9,45. Treatment for tuberculosis may also be complicated by 
HIV/AIDS patients’ higher risk of adverse reactions from anti-tubercular drugs.  
 
2.1.3. Preventive Stage 
The third element in tuberculosis control efforts has been preventing infection with M. 
tuberculosis through vaccination, administration of prophylaxis, or isolation of infectious 
patients. 
Although immunizations have long been considered a powerful tool in public health 
efforts to control communicable diseases, the Bacille-Calmette Guerin (BCG) vaccine 
remains the only means of immunizing against M. tuberculosis 46. Derived from 
Mycobacterium bovis, BCG is most effective at preventing miliary or meningeal forms of 
tuberculosis in children 46. In spite of these benefits, the vaccine has shown a wide range of 
efficacy, with BCG vaccines often being least effective in countries with the highest disease 
burdens from M. tuberculosis 47. This variability is often attributed to genetic differences in 
vaccines and decreased immunity caused by co-infection with environmental mycobacteria 
and intestinal helminthes 47,48. BCG vaccines are also not recommended for HIV-infected 
individuals 6. 
A second method for preventing infection with tuberculosis has been providing 
prophylactic treatment to high-risk patients such as household contacts of patients with 
tuberculosis 49. Isoniazid remains the most common form of prophylaxis, and exhibits 
bactericidal effects against M. tuberculosis 50. Despite its efficacy, widespread 
implementation of isoniazid programs are often avoided due to concerns regarding the 
development of drug-resistant strains of M. tuberculosis 51. Prophylaxis is usually not 
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provided with the same level of patient support or observation that is found in DOTS 
programs for tuberculosis. Intermittent use of an antibiotic ultimately decreases the level of 
protection provided by prophylaxis against tuberculosis infection 52,53. If during the process, a 
patient does become develop tuberculosis disease then the prophylaxis would become mono 
drug-therapy, potentially causing amplification of drug-resistance. The potential for 
developing drug resistance may be particularly high for HIV/AIDS patients, due to 
malabsorption of drugs and a higher risk of undetected tuberculosis 38-43,54. As previously 
mentioned, HIV/AIDS patients are less likely to exhibit chest cavitation, more likely to 
present false-negative tuberculin skin test results, and at increased risk of extra pulmonary 
forms of tuberculosis, depending on their level of immunosuppression. 
The most commonly used method for preventing tuberculosis is by minimizing the 
potential for airborne transmission of tuberculosis 55. This can be done in a number of ways, 
including administrative controls to isolate infectious patients; environmental controls such 
as modifying general ventilation or the use of air cleaning methods such as High Efficiency 
Particulate Air (HEPA) filters, or ultraviolet irradiation of ducts; and providing respiratory 
protection through the use of respirators or masks 55. Screening health care workers for 
pulmonary tuberculosis through yearly chest x-rays can also be an important element in 
preventing transmission due to their increased risk of acquiring tuberculosis, and their 
potential to act as transmission vectors within a health care setting 56,57. Extra pulmonary and 
non-infectious forms of childhood tuberculosis are usually not considered of primary 
importance in transmission control efforts due to the low probability of infectious particles 
being aerosolized 58.  
 
2.2. MODS: A Potential Diagnostic Solution? 
The identification of a rapid yet cost-efficient method for detecting tuberculosis and its drug 
susceptibility status remains a key limitation for current global efforts to control tuberculosis 
59. Although molecular techniques such as line probe assays can be used to detect drug-
resistance in samples in under days, cost and the need for complex laboratory facilities often 
limits their utility in the developing world 28. In addition to having a lower sensitivity for 
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smear-negative samples, the molecular methods often detect a limited number of mutations 
making transferability of technology for other pathogens difficult 28,29. Cumulative evidence 
suggests that the Microscopic Observation Drug Susceptibility (MODS) assay may be one 
potential candidate for meeting these goals 60-66. 
The development of MODS was based on three principles, namely: [1] M. 
tuberculosis can be cultured more quickly in liquid rather than solid media; [2] Culture 
growth of M. tuberculosis can be detected more rapidly using a light microscope instead of 
with the naked eye; and [3] M. tuberculosis grows in distinctive strings and tangles within 
liquid culture, making general species identification based on morphology at the microscopic 
level possible. Its cost can range between $0.53 to $0.77 US per sample to perform 
depending on the type of test being conducted (e.g., culture versus drug susceptibility status) 
and regional differences in labor and laboratory costs 61,67.  Using Middlebrook 7h9 broth, 
MODS can detect both culture and drug-susceptibility status for M. tuberculosis when 
antibiotics are introduced into broth. 
Several studies indicate that culture and drug-susceptibility results for the MODS 
method are tightly correlated with reference standard methods 60-66. Table 2.2 shows that 
concordance results for MODS range from 92 to 98 percent for culture detection; 99 to 100 
percent for rifampicin testing; 97 to 100 percent for isoniazid testing; 58 to 95 percent for 
ethambutol testing; and 51 to 92 percent for streptomycin testing. The median time to 
culture-positivity for MODS ranges from seven to nine days. Research has also revealed little 
differences in the diagnostic validity of MODS using direct versus indirect testing 65; diluted 
versus undiluted sputum samples 62; smear negative versus smear positive sputum samples 64; 
and sputum samples obtained before and during tuberculosis treatment 64. More recently, the 
MODS method was validated for culture-based testing of pleural and cerebral spinal fluid 
from adults 67,68, as well as gastric aspirate, nasopharyngeal aspirate and stool specimens 
from children 69. 
Despite these promising results, several issues remain for the optimization of MODS. 
First, because the cording patterns of M. tuberculosis in Middlebrook 7h9 broth are similar to  
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Table 2.2. Clinical evidence regarding the diagnostic validity of the Microscopic 
Observation Drug Susceptibility (MODS) assay for detecting pulmonary tuberculosis 
and its drug-susceptibility status. 
 
Author 
(Reference) 
Year 
Origin of Samples 
 
Study Sample 
Culture Detection Drug Susceptibility Testing 
Reference 
Standard Test 
Diagnostic Results Reference 
Standard Test 
Diagnostic Results 
 
Caviedes 
61 
2000 
Peru 
172 samples from 
patients suspected 
of having 
tuberculosis based 
on presence of 
clinical 
manifestations 
and/or smear 
positive sample 
 
 
 
Middlebrook 
7h11 
 
Sensitivity:           92% 
Medium TCP:     9 days  
          (Range: 4 - 31 days) 
 
Microplate 
Alamar Blue 
Assay  
(MABA) 
         Concordance 
Rifampicin:       99%               99% 
               (0.5  μg/mL)   (1.0 μg/mL) 
 
Isoniazid:     100%             100% 
                    (0.1  μg/mL)    (0.4 μg/mL) 
 
 
 
Park 
65 
2000 
Peru 
 
53 Isolates from 
patients at risk of 
MDR-TB 
 
 
 
n/a 
 
 
 
n/a 
 
Middlebrook 
7h10 Agar 
 Concordance 
Rifampicin:      100% 
 (2.0 μg/mL) 
 
Isoniazid:      100% 
 (0.1 μg/mL) 
 
Ethambutol:       70%         58% 
                       (2.5 μg/mL)     (7.5 ug/mL) 
 
Streptomycin:       77%        51% 
                       (2.0 μg/mL)     (6.0 μg/mL) 
 
 
 
 
Moore 
64 
2004 
Peru 
207 Pre-treatment 
Samples 
69 On-treatment 
Samples 
 
Subjects part of two 
cohorts: 
(i) Patients 
receiving DOTS 
treatment for 
tuberculosis 
(ii) Patients with 
respiratory 
symptoms 
 
Lowenstein-
Jensen 
 
Sensitivity:             94% 
Median TCP:       8 days 
Microplate 
Alamar Blue 
Assay  
(MABA) 
&  
Tetrozolium 
Microplate 
Assay 
(TEMA) 
               Pre-treatment   On-Treatment 
 Sample             Sample 
Rifampicin (1.0 μg/mL): 
   Sensitivity  100% 92.9% 
   Specificity  98.3% 89.7% 
 
Isoniazid (0.4 μg/mL): 
   Sensitivity  81.1% 90.3% 
   Specificity  96.9% 98.3% 
 
Ethambutol (2.5 μg/mL): 
   Sensitivity  42.3% 64.7% 
   Specificity  91.9% 91.1% 
 
Streptomycin (6.0 μg/mL): 
   Sensitivity  44.4% 50.0% 
   Specificity  98.3% 98.0% 
 
 
 
Moore 
63 
2006 
Peru 
3760 Sputum & 
gastric samples 
obtained from: 
 
(i) Patients with 
suspected 
tuberculosis 
(ii) Patients with 
suspected 
tuberculosis who 
were at high risk of 
 
Lowenstein-
Jensen  
&  
MbBacT 
 
Sensitivity:         97.8% 
Median TCP:     7 days 
                (IQR: 6 - 8 days)  
MbBacT  
&  
Lowenstein-
Jensen 
                 Concordance Kappa 
Isoniazid: 97%  0.89 
(0.4 μg/mL) 
 
Rifampicin: 100%  1.0 
(1.0 μg/mL)    
 
Ethambutol: 95%  0.71 
(2.5 μg/mL)    
 
Streptomycin: 92%  0.72 
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MDR-TB 
(iii) Unselected 
hospitalized HIV-
infected patients 
 
 
(2.0 μg/mL)    
 
 
 
Arias 
60 
2007 
Brazil & Honduras 
180 Respiratory 
samples  (one 
specimen per 
patient) obtained 
from patients with: 
(i) Suspected 
tuberculosis 
treatment failure 
(ii) Suspected 
tuberculosis relapse 
(iii) Treatment 
default 
(iv) Close contact 
with MDR-TB 
patient 
 
 
 
 
Lowenstein-
Jensen  
&  
MGIT 960 
 
      Per-subject Analysis 
Sensitivity:         97.5%    
              ( 95% CI: 96 - 99) 
Specificity:        94.4%  
               (95% CI: 93 - 95) 
Median TCP:    7 days  
              (IQR: 5 - 10 days) 
 
 
 
 
n/a 
 
 
 
n/a 
 
 
 
 
 
 
Mello 
62 
2007 
Brazil & Honduras 
1369 Respiratory 
Samples obtained 
from 854 subjects 
who had: 
(i) New suspected 
pulmonary 
tuberculosis 
(ii) Suspected 
treatment failure 
(iii) Suspected 
relapse 
(iv) Treatment 
default 
 
 
 
 
 
 
 
n/a 
 
 
 
 
 
n/a 
 
 
 
 
Lowenstein-
Jensen 
                    Undiluted        1:10 Diluted 
                      Sample   Sample 
Isoniazid (0.1  μg/mL): 
   Sensitivity     96.7%     96.7% 
     95%CI      (92 – 99)   (92 – 99) 
   Specificity     78.4%     83.0% 
     95%CI      (74 – 81)   (78 – 85) 
 
Rifampicin (2.0  μg/mL): 
   Sensitivity     96.0%     96.0% 
      95%CI     (90 – 99)   (90 – 99) 
   Specificity     82.9%     84.8% 
     95%CI      (79 – 85)   (81 – 87) 
 
 
Ejigue 
66 
(2008) 
Ethiopia 
 
 n/a n/a  
BACTEC  
& 
MGIT 
 
Multi-drug Resistance (combined):  
  Sensitivity: 95%         Specificity: 100% 
  Accuracy: 98.3%       Kappa = 0.981           
TCP= Time to culture-positivity; CI=Confidence Interval; IQR=Interquartile Range 
 
 
those of Mycobacterium chelonae and M. smegmatis 61,63, lab readers must be trained to 
intuitively differentiate each species by their culture rates: both species overgrow rapidly as 
compared to M. tuberculosis. Second, although MODS has been shown to accurately detect 
rifampicin and isoniazid resistance in M. tuberculosis, detection results for ethambutol and 
streptomycin results have been poor. Possible explanations for these results have included 
sampling errors and a tendency to overcall drug resistance 65. The critical concentrations of 
MODS for both of these drugs have also never been identified. Third, the use of MODS with 
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other anti-tubercular drugs such as pyrazinamide, ciprofloxacin, capreomycin, kanamycin 
and amikacin has also not been validated. 
An additional concern with using MODS has been the occupational hazards from 
transmitting M. tuberculosis through liquid culture 70. In hospital laboratories, where the 
infectious nature of sputum and gastric samples are initially unknown, the risk of 
occupational transmission may be high. Two studies found that hospital lab personnel were  
three to nine times more likely to be infected with M. tuberculosis as compared to the general 
population. However, lab-associated cases are very difficult to identify due to the long 
incubation period for M. tuberculosis and the unknown outside sources of infection that 
hospital personnel may be exposed to, particularly when the prevalence of tuberculosis is 
high in the general population 71.  
As with other liquid culture methods, the risk of lab transmission with MODS is 
greatest if microbial droplets or aerosols produced during sample decontamination were to be 
inhaled or if cultures were to splash or spill during the inoculation phase  72,73. Aerosols can 
be ubiquitous in nature and difficult to detect 72.  However, the risk of infection during 
traditional processing of samples for MODS can be minimized by using standard laboratory 
equipment such as biological safety cabinets, centrifuge safety caps, sealed rotors and plastic 
screw-lid vials 73. Additionally, efforts are being made to develop agar versions and liquid  
cultures for MODS, which do not require decontamination or centrifugation of samples 74. As 
for accidental spillage of liquid culture when microplates are being transported from the 
incubator to the microscope, this problem can be avoided by placing inoculated microplates 
in polyethylene Ziploc bags immediately following sample inoculation 73,75. Sealing each 
microplate well with adhesive tape also avoids having to repeat sputum testing, if an 
inoculated plate falls during sample processing and the sputum must be re-cultured. More 
importantly, training and experience in handling M. tuberculosis samples can significantly 
reduce the overall risk of lab-associated infections 73. 
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2.3. The synergistic effect between HIV/AIDS and tuberculosis 
In more recent years, efforts to control tuberculosis have been hampered by the emergence of 
HIV. The link between HIV/AIDS and tuberculosis is most evident in the epidemiological 
burden of tuberculosis. While worldwide rates of pulmonary tuberculosis have been dropping 
since DOTS was instituted in 1995, in settings with a high prevalence of HIV/AIDS the 
incidence of pulmonary tuberculosis continues to increase.  
HIV often targets IFN-γ and CD4+ T lymphocytes needed to protect patients not only 
from infection with tuberculosis but also its progression from latent to active disease 76,77. It 
is estimated that while the lifetime risk of developing active tuberculosis disease from latent 
infection among otherwise healthy individuals is 10%, this risk increases to 50% for those 
infected by HIV.  
Isoniazid can be used both as a preventive therapy to lower a patient’s risk of 
infection with M. tuberculosis, as well as treatment for latent tuberculosis. However, it is 
rarely used as part of a widespread public health initiative to control for tuberculosis due to 
long-term difficulties in drug delivery and concerns regarding the development of isoniazid-
resistant forms of tuberculosis 78. The use of prophylaxis can be complicated by difficulties 
in diagnosing HIV-infected individuals with tuberculosis, who depending on the extent of 
immunosuppression may be more likely to present with smear-negative disease, atypical 
chest radiographs, false negative tuberculin skin test results and present with extrapulmonary 
rather than pulmonary forms of disease 6,26. Similarly, testing of HIV-positive patients for 
latent tuberculosis is often more difficult since infection status is based on immune responses 
for M. tuberculosis (which are frequently suppressed by HIV) rather than direct identification 
of the pathogen 79.  
The therapeutic management of tuberculosis can also be problematic when used in 
conjunction with Highly Active Antiretroviral Therapy (HAART) for HIV-infection. Aside 
from HIV-infected patients being at increased risk of side effects from anti-tubercular drugs,  
drug interactions between protease inhibitors and non-nucleoside reverse transcriptase 
inhibitors (standard drugs used to treat HIV) with rifampicin (the standard first line drug for 
tuberculosis), can significantly lower plasma concentrations of antiretroviral drugs 80.  
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Figure 2.2. Annual mortality rates from pulmonary tuberculosis in England, from 1838 
to 1970. 
 
 
 
 
 
 
 
 
 
 
 * Record collection of mortality rates began in 1838. 
Source: McKeown T. Les déterminants de l’état de santé des populations depuis trois siècles: le 
comportement, l’environnement et la médicine. In: Bozzini, L, Renauld M, Gaucher, D, Llambas-Wolff. 
Médecine et société. Les années 80. Editions Coopératives Albert Saint-Martin: Montréal. 1981. 
 
 
Rifampicin can be replaced by rifabutin when treating HIV-infected patients. However, 
complications with treatment often cause physicians to postpone the use of HAART among 
HIV-infected patients until after the initial phase of tuberculosis treatment is completed 6.   
This synergy between HIV/AIDS and tuberculosis has led to renewed calls by the 
medical community to strengthen the public health infrastructure in many resource-
constrained settings, namely by improving health care systems, diagnostic laboratories, 
human resources and public health services for the disease 4,5. It has also been suggested that 
current public health programs for tuberculosis and HIV be better integrated, on the basis that 
the “whole may be greater than the parts” when it comes to dealing with HIV-associated 
tuberculosis 81.  
Yet, while current failings in the biomedical approach towards tuberculosis control 
may be due to the limited resources in many developing countries, historical demographics 
for tuberculosis suggest that other explanations may exist. It has been noted that reductions in 
mortality from pulmonary tuberculosis were achieved in England (figure 2.2) several decades 
before the discovery of the tubercle bacilli, the advent of anti-tubercular agents or the 
discovery of BCG vaccines (i.e., the root elements of a biomedical framework for 
tuberculosis control) 82. Such an observation raises complex questions, including whether 
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declining trends during the middle 1800’s were a reflection of natural selection or 
improvements in social conditions 82,83.  
 Tuberculosis has long been recognized as a disease of extreme poverty 84. However, 
if an increase in the prevalence of pulmonary tuberculosis among HIV-infected individuals is 
due to socio-economic differences, then why are incidence rates for tuberculosis only 
increasing among HIV-infected patients and not among other poverty-stricken groups? More 
importantly, why have other poverty-related diseases such as malaria, not been impacted by 
AIDS to the same extent as pulmonary tuberculosis?  
 
2.4. HIV/AIDS: A cause of multi-drug resistant tuberculosis?  
Reports of MDR-TB and XDR-TB outbreaks among hospitalized AIDS patients and prison 
populations with a high prevalence of HIV have also raised concerns regarding a potential 
link between AIDS and multi-drug resistant forms of tuberculosis 85-93. While the effect of 
HIV/AIDS on the incidence of tuberculosis has been well described 1, the role of this factor 
in relation to multidrug resistance is less certain 10. The low prevalence of multi-drug 
resistance and HIV in many tuberculosis settings, and the lack of drug-susceptibility data in 
joint population-based surveys of HIV and tuberculosis has made studying the association 
between HIV/AIDS and MDR-TB more difficult 34.  
The development of drug-resistance during anti-tubercular treatment may be 
particularly problematic for AIDS patients due to their increased risk of gastrointestinal 
malabsorption 9,38-43,54. This can lead to a lower bioavailability of anti-tubercular drugs in the 
bloodstream thus increasing a patient’s risk for developing drug-resistance 9,38-43,54. Many of 
these conditions may be further complicated by the introduction of the Beijing strain into a 
population of AIDS patients. In addition to this strain being more virulent, it is also more 
commonly associated with amplifications in drug-resistance. 
Although observational studies and randomized clinical trials have confirmed these 
findings by identifying a link between AIDS and the development of resistance to rifamycins 
(the family group of rifampicin) 9,10,4, several papers have noted that outbreaks of MDR and 
XDR-TB usually occurred among AIDS patients who were previously uninfected with 
18 
 
 
tuberculosis and were living in industrialized countries where the prevalence of tuberculosis 
was low to begin with 8,11,17,8. In other words, patients had probably not developed drug-
resistance from past treatment of tuberculosis.  
 Ultimately, this has led to alternative theories for outbreaks of MDR and XDR-TB. 
They include diagnostic or treatment delays for tuberculosis; a higher risk of defaulting from 
DOTS due to adverse drug reactions; and poor infection control measures such as placing 
AIDS patients in the same ward regardless of whether they were infected with pulmonary 
tuberculosis or not 6,10,94. However, inferring causal links from outbreak studies can be 
difficult since they are frequently evaluated using a case-only rather than a case-comparison 
or case-control approach. It is also interesting to note that during non-outbreak periods of 
time, few epidemiological studies have identified an association between HIV/AIDS and 
drug-resistant tuberculosis 95. 
 
2.5. Summary 
Tuberculosis remains a major cause of morbidity and mortality 1-3. Although biomedical 
strategies such as DOTS have helped to decrease the global incidence of tuberculosis, efforts 
to control tuberculosis are currently being hampered by a continuing rise in the prevalence of 
HIV/AIDS (a major risk factor for tuberculosis). At the same time, outbreaks of MDR-TB 
among AIDS populations have led to concerns regarding a potential link between HIV/AIDS 
and the development of drug-resistance. Although this problem is frequently attributed to 
pathophysiological characteristics of HIV/AIDS and deficiencies in biomedical efforts to 
control tuberculosis, it is currently unclear whether an association between MDR-TB and 
HIV/AIDS actually exists.  
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CHAPTER 3.  
 Overview and Objectives 
 
It is against this backdrop that the first part of this thesis aimed to develop a knowledge 
foundation regarding the underlying causes that lead to outbreaks of MDR-TB among 
HIV/AIDS patients.  
To do this, we made use of several datasets collected as part of a grand study of 
tuberculosis between 1995 and 2005 in Lima, Peru. During this period, AIDS patients were 
experiencing a widespread outbreak of MDR-TB. The Ministry of Health was also on the 
verge of implementing a comprehensive national MDR-TB program which included drug-
susceptibility testing. Before the MDR-TB program was fully instituted in 2005, drug-
susceptibility testing took on average five months (almost equivalent to one full round of 
DOTS treatment for newly diagnosed cases). At the time, patients with and without AIDS in 
Lima, Peru were also being referred to separate hospitals for medical care, thus providing an 
opportunity to identify and compare two contemporary groups of patients exposed to 
pulmonary tuberculosis during an ongoing outbreak of MDR-TB in Lima, Peru, based on 
cohort prevalence of AIDS.  
In the second part of this thesis, the knowledge framework regarding MDR-TB 
outbreaks was used to develop public health strategies for preventing tuberculosis among 
HIV/AIDS patients. This included using the Microscopic Observation Drug Susceptibility 
(MODS) assay to screen hospitalized AIDS patients for tuberculosis. At the technology 
development level, we also refined the MODS assay in order to detect drug-susceptibility 
status in M. tuberculosis. 
 
The specific objectives of this thesis include: 
 
Knowledge Generation: 
 
Study #1 
1. To investigate the role of AIDS in an epidemic of MDR-TB among patients receiving 
DOTS treatment for pulmonary tuberculosis between 1999 and 2005 in Lima, Peru. 
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1.1. To describe the prevalence of MDR-TB among AIDS and non-AIDS patients. 
1.2. To estimate the proportion of patients who acquired primary versus secondary 
multidrug resistance during DOTS. 
1.3.  To describe the strains and clusters of M. tuberculosis among AIDS and non-
AIDS patients receiving DOTS treatment for pulmonary tuberculosis. 
1.4. To identify risk factors for infection with the epidemic clone of MDR-TB. 
 
Study #2 
2. To characterize the prevalence and factors associated with stool shedding with 
mycobacteria among AIDS patients in Lima, Peru. 
2.1.  To calculate the frequency and pattern of shedding viable mycobacteria in the 
sputum and stool of patients at two different stages in the natural history of 
pulmonary tuberculosis. 
2.2.  To identify factors associated with shedding mycobacteria in the stool of 
AIDS patients in the later stages of tuberculosis disease.  
 
Knowledge Integration/Technology Transfer: 
 
Study #3 
3. To begin developing screening strategies for tuberculosis among hospitalized HIV/AIDS 
patients using the Microscopic Observation Drug Susceptibility assay.  
3.1.  To evaluate how screening hospitalized patients using the standard diagnostic 
criteria of sputum microscopy, symptom review and chest radiography, 
compares with an alternative approach of using MODS to screen all patients. 
3.2.  To determine whether MODS screening should be targeted to pre-selected sub-
groups of patients 
3.3.  To identify the clinical impact of targeted versus blanket screening using 
MODS. 
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Technology Development: 
 
Study #4 
4. To define the optimal critical concentration needed for detecting drug resistance in M. 
tuberculosis using the Microscopic Observation Drug Susceptibility assay.  
4.1.  To identify and validate the critical concentration needed to detect ethambutol 
and streptomycin resistance in M. tuberculosis using MODS. 
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CHAPTER 4.  
Role of AIDS in an epidemic of multi-drug resistance among 
patients receiving Directly Observed Therapy Short-Course 
for pulmonary tuberculosis 
Knowledge Generation 
For this first study, we identified the underlying factors associated with an outbreak of MDR-TB 
among AIDS patients receiving DOTS treatment for pulmonary tuberculosis in Lima, Peru. 
 
 
 
4.1. Study Summary 
 
Background:  We examined the role of AIDS in an epidemic of multi-drug resistant 
tuberculosis (MDR-TB) among patients receiving Directly Observed Therapy Short-Course 
(DOTS) for pulmonary tuberculosis in Lima, Peru between 1999 and 2005. Methods: We 
identified two patient populations receiving DOTS based on group prevalence of AIDS 
[n=205 in AIDS cohort; n=386 in non-AIDS cohort]. Before starting treatment, all patients 
had physical exams and were interviewed. Sputum samples were collected at enrolment, at 
week 1, month 1, month 2, and month 4 of tuberculosis treatment and once at the end of 
treatment. We obtained DNA fingerprints for MDR-TB samples using spoligotype and 
IS6110 Restriction Fragment Length Polymorphism. Results: Patients in the AIDS cohort 
were at increased risk of presenting MDR-TB at the start of treatment [Crude Odds Ratio 
(OR): 2.89, 95% CI: 1.4 to 5.8], and at increased risk of acquiring multi-drug resistance 
during treatment [Crude Rate Ratio: 2.07, 90% CI: 1.0 to 4.3], relative to those in the non-
AIDS cohort. 92% (11/12) of AIDS cohort patients who developed multi-drug resistance 
during treatment had acquired primary drug resistance, from which 55% (6/11) were 
superinfected by one particular strain of Mycobacterium tuberculosis. Although this strain 
was more common among AIDS cohort patients (χ2=5.00, p-value=0.02), we found no cohort 
difference in the risk of superinfection with this strain, after adjusting for patients’ baseline 
risk of exposure to circulating strains [Standardized Incidence Ratio (SIR) for AIDS cohort: 
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1.63, 95% CI: 0.5 to 3.8 and for non-AIDS cohorts 1.75, 95% CI: 0.4 to 5.1]. Conclusion: 
An epidemic of MDR-TB among AIDS patients receiving DOTS for pulmonary tuberculosis 
was due to probable super-infection with one specific strain of M. tuberculosis rather than the 
development of secondary drug-resistance. While this epidemic strain was more common 
among patients in the AIDS cohort, risk of super-infection did not differ between patients in 
the AIDS and non-AIDS cohort, suggesting that another factor possibly associated with 
diarrhea may be contributing to the strain’s high prevalence among AIDS patients. 
 
4.2. Background 
 
In recent years, while the global incidence of tuberculosis disease has declined, the incidence 
of tuberculosis has increased in regions where HIV/AIDS is common 1. This in conjunction 
with outbreaks of multi-drug resistant (MDR-TB) and extremely drug-resistant (XDR-TB) 
tuberculosis among hospitalized AIDS patients and prison populations with a high 
prevalence of HIV, have caused some to suggest that we are now entering the worst epidemic 
of tuberculosis since the advent of the antibiotic era 85-93,96,97 
Anti-tubercular treatment may be particularly problematic for AIDS patients, due to 
an increased risk for gastrointestinal malabsorption of anti-tubercular drugs 38-43,54. Lower 
bioavailability of antibiotics in the bloodstream can increase a patient’s risk of developing 
drug-resistance 9. AIDS patients are also more likely to default from DOTS programs, due in 
large part to adverse drug reactions experienced during treatment 6. Several observational 
studies and randomized clinical trials have confirmed these findings by identifying a link 
between AIDS and the development of resistance to rifamycins (the family group of 
rifampicin) 8,9,45. The introduction of the Beijing strain into populations with a high 
prevalence of AIDS may also hamper effective management of tuberculosis due to the 
strain’s increased virulence and greater susceptibility to amplification of drug-resistance, 
relative to other strains of Mycobacterium tuberculosis 10,98.  
Despite this evidence, several papers note that reported outbreaks of MDR-TB and 
XDR-TB usually occurred among AIDS patients who were previously uninfected with 
tuberculosis and living in industrialized countries where the prevalence of tuberculosis was 
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low 85-93,96. Many of these outbreaks were attributed to diagnostic and treatment delays, as 
well as poor infection control measures such as placing AIDS patients in the same ward 
regardless of whether they were infected with pulmonary tuberculosis or not 10,94. However, 
inferring causal links from these studies may be difficult since these outbreaks were 
frequently evaluated using a case-only rather than a case-comparison approach. 
In light of these limitations, we examined the underlying factors associated with an 
epidemic of multi-drug resistance in Lima, Peru, by comparing an AIDS and non-AIDS 
population receiving Directly Observed Treatment Short-Course (DOTS) for pulmonary 
tuberculosis.   
 
4.3. Methods 
4.3.1. Study Setting:  
Data collection occurred between May 1999 and April 2005 in Lima, Peru. During this 
period, AIDS and non-AIDS patients who were living in the same community were often 
referred to separate hospitals for medical care, thus enabling us to compare two concurrent 
patient populations exposed to MDR-TB based on group prevalence of AIDS. During our 
study, the Peruvian Ministry of Health was in the process of implementing a comprehensive 
national MDR-TB program which included drug-susceptibility testing for MDR-TB. The 
program was fully instituted in 2005 99. Before then, testing for MDR-TB took on average 
five months (i.e., almost equivalent to the duration of one round of DOTS treatment) 100. 
 
4.3.2. Study Populations: 
We identified two patient cohorts about to commence DOTS treatment for pulmonary 
tuberculosis. The first group (AIDS cohort) consisted of AIDS patients attending the 
Infectious Disease Clinic of the Hospital Dos de Mayo, the main referral hospital for persons 
with AIDS in Lima, Peru. The second group (non-AIDS cohort) consisted of patients referred 
to the Pulmonary Clinic of the Hospital Maria Auxiliadora. Patients were excluded from our 
study if they experienced an adverse reaction to anti-tubercular drugs. Our final analysis 
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included patients who attended at least 90% of treatment days in the DOTS program and had 
bacteriological confirmation of Mycobacterium tuberculosis in sputum (please refer to 
Appendix 2 and 3). All subjects provided written informed consent. Institutional review 
boards at Johns Hopkins Bloomberg School of Public Health and A.B. PRISMA approved 
the original study protocols. 
 
4.3.3. Data Collection: 
Figure 4.1 illustrates that before the start of DOTS treatment (day 0), a complete physical 
examination was conducted. This included measuring weight in kilograms, height in meters, 
and body mass index (BMI) in kilograms/meters2, and collecting blood samples. A 
questionnaire was completed regarding socio-demographic information and medical history. 
Two consecutive sputum samples were obtained at enrolment (day 0), as well as during 
follow-up visits at week 1, month 1, month 2, month 4 of treatment, and once at the end of 
treatment. A small proportion of patients also provided sputum samples at week 2 of 
treatment. A study physician conducted the study interview and physical exams (please refer 
to Appendix 4). All laboratory specimens were sent for testing to the research laboratory at 
the Universidad Peruana Cayetano Heredia in Lima, Peru.  
 
4.3.4. Laboratory Methods and Definitions:  
Sputum samples were tested for smear status using Auramine Smear Microscopy; culture 
status using Lowenstein-Jensen or Middlebrook 7h9 Broth (Difco, Detroit, Mich.); and drug-
susceptibility status using the Microplate Alamar Blue Assay (MABA) 101. Samples were 
categorized as drug-resistant if the Minimum Inhibitory Concentration cut-off for MABA 
was greater than 0.25 µg/mL for isoniazid, and greater than 0.25 µg/mL for rifampicin 102. If 
samples were resistant to both isoniazid and rifampicin, they were classified as multi-drug 
resistant (MDR). Patients had drug-susceptible tuberculosis at study entry if all sputum 
samples they produced were susceptible to isoniazid and rifampicin before and during the 
first two weeks of anti-tubercular treatment. Patients who developed drug-resistance after at 
least one month of treatment were classified as having acquired drug-resistance 103. 
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DNA fingerprinting by spoligotype was performed on the first sputum sample 
collected at study entry and on the first sample collected from patients at the time that they 
acquired drug-resistance 104. We identified strain genotypes by comparing octal code 
numbers for each isolate with those recorded in the SpolDB4 database 105. Strain conversion 
status for patients who acquired drug-resistant tuberculosis was identified by comparing the 
strain genotype for isolates collected from a patient at baseline and at the time that they 
acquired drug-resistance. We identified clones within each strain genotype by conducting 
IS6110 restriction fragment length polymorphism (RFLP) on isolates from all MDR-TB 
patients in the AIDS cohort and MDR-TB patients in the non-AIDS cohort who were 
infected with Lam9 or T1 strains of M. tuberculosis. IS6110 RFLP was conducted using 
previously described methods 106. We used primers INS-1 and INS-2 to amplify probes to a 
length of 245 base pairs. Isolates with matching IS6110 RFLP band patterns were ascertained 
manually and with PRO-SCORE (DNA Proscan, Nashville, TN).  
To check for evidence of laboratory cross-contamination in patients who acquired 
multi-drug resistance but only produced one multi-drug resistant sputum sample during 
follow-up, we compared DNA fingerprints for the sputum sample in question with 
fingerprints for all other multi-drug resistant samples processed on the same day. We 
identified two patients who acquired MDR-TB and whose IS6110 RFLP fingerprint matched 
another MDR-TB sample processed on the same day. The sputum sample results from both 
these patient were excluded from our final analysis. 
We measured CD4 lymphocyte counts of patients within the AIDS cohort using the 
Manual CD4 Cell Count Kit (Coulter). Patients in the non-AIDS cohort were tested for HIV-
1 and HIV-2 antibodies using enzyme-linked immunosorbent assay (ELISA). 
 
4.3.5. Data Analysis:  
Our analysis had six main objectives. The first was to identify whether patients in the AIDS 
cohort were at greater risk of: 1. presenting MDR-TB at the start of DOTS treatment for 
tuberculosis; and, 2. acquiring multidrug resistance during DOTS, if infected with drug-
susceptible tuberculosis at the start of treatment. For each study cohort, we estimated the 
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proportion of patients with drug-resistant pulmonary tuberculosis at the start of DOTS treatment 
(cohorts compared using the odds ratio), and the incidence of acquiring drug-resistant pulmonary 
tuberculosis per 1000 person-months of treatment (cohorts compared using the incidence rate 
ratio).  
Our second objective was to: 1. identify for each study cohort the proportion of drug-
susceptible patients being treated for tuberculosis with DOTS who developed primary versus 
secondary multidrug resistance during treatment; and, 2. determine whether patients in the AIDS 
cohort were more likely to acquire secondary multidrug resistance during treatment as compared 
to patients in the non-AIDS cohort. We identified strain conversion status for each patient who 
acquired drug-resistant tuberculosis by comparing the strain genotype for isolates collected from 
a patient at baseline and at the time that they acquired multi-drug resistance.  We defined primary 
drug-resistance as infection with a drug-resistant strain; and, secondary drug-resistance as the 
development of drug-resistance within a previously susceptible strain of M. tuberculosis (Figure 
4.6). Using strain conversion status, we classified patients as having acquired primary drug-
resistance if their strain of MDR-TB was different than the drug-susceptible (DS) TB strain at 
baseline. Patients were classified as having acquired secondary multidrug resistance if the strains 
for both DS-TB at baseline and acquired MDR-TB were the same. We compared the proportion 
of patients who acquired secondary multidrug resistance from each study cohort using the 
Fisher’s Exact test. 
Our third objective was to determine whether the outbreak of multi-drug resistance 
among the AIDS cohort was due to a particular strain of M. tuberculosis. For each study cohort, 
we calculated the frequency distribution of strain genotypes among patients with MDR-TB at 
baseline and patients who acquired primary multidrug resistance during DOTS treatment. We 
then compared the strain distributions from each study cohort using the Chi-square test. We 
classified any strain that occurred more frequently in the AIDS cohort as an epidemic strain of 
MDR-TB. 
Our fourth objective was to determine whether the risk of superinfection with the 
epidemic strain differed between patients in the AIDS and non-AIDS cohort, after adjusting for 
the patients’ baseline risk of exposure to all circulating strains. This was done by calculating the 
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standardized incidence ratio for acquiring an MDR-TB strain during tuberculosis treatment. For 
each study cohort, we estimated a strain’s standardized incidence ratios by dividing the observed 
number of cases by the expected number of cases. We determined the expected number by 
assuming that the distribution of strains among patients who acquired MDR-TB strains would be 
the same as those with MDR-TB at the start of treatment. Confidence intervals were determined 
using a Poisson distribution.  
 Our fifth objective was to characterize whether AIDS patients infected with the 
epidemic strain of M. tuberculosis shared a common clone. Using RFLP data, we identified 
the number of clones per strain type found in isolates from patients in the AIDS cohort, as 
well as the number of clusters per clone type found to be circulating within the AIDS cohort. 
We also identified whether cluster clones isolated from patients in the AIDS cohort were 
circulating within the non-AIDS cohort, by reviewing RFLP data from patients in the non-
AIDS cohort who shared the same MDR-TB strain as cluster strains found in the AIDS 
cohort. 
Our final objective was to identify which factors may have contributed to the 
epidemic clone of MDR-TB becoming predominant among AIDS patients. Using data from 
MDR-TB patients in both the AIDS and non-AIDS cohorts, we estimated for each factor the 
univariate odds ratio using an exact logistic regression model and the likelihood ratio for a 
positive and negative test using standard formula 107. We assessed the measure of association 
for the following covariates: sputum smear stain status [positive or negative], HIV-infection 
status [positive or negative]; sex [male or female]; previous infection with TB [yes or no]; 
known contact with a TB case during the previous two years [yes or no]; known 
hospitalization during the previous two years [yes or no]; cough [yes or no]; productive 
cough [yes or no]; fever [yes or no]; shortness of breath [yes or no]; hemoptysis [yes or no]; 
recent weight loss [yes or no]; loss of appetite [yes or no]; night sweats [yes or no]; fatigue 
[yes or no]; past prophylaxis for TB [yes or no]; previously hospitalized [yes or no]; 
underweight [yes or no]; and presence of diarrhea [yes or no]. We classified any patient with 
a BMI less than 18.5 kg/m2 as being underweight 108. 
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We calculated confidence intervals for all measures using a two-sided alpha of 0.05. 
We conducted all statistical analysis using STATA v.7 (College Station, TX).  
 
4.3.6. Role of the Funding Source:  
The funding source had no role in study design, data collection, data analysis, and data 
interpretation, writing of the manuscript or the decision to publish. 
 
4.4. Results 
From 1999 through 2005, we recruited 730 patients referred to the Peruvian National 
Tuberculosis Control Program for treatment of pulmonary tuberculosis. 712 patients 
provided sputum samples before the start of DOTS treatment (figure 4.2). 601 patients were 
culture-positive for M. tuberculosis and thus deemed eligible to participate in our study. 10 or 
2% of these patients were missing drug-susceptibility results and thus excluded from our 
analysis.  
Patients in the AIDS cohort resided in more geographically dispersed locations, 
relative to those in the non-AIDS cohort (figure 4.3). Patients in the AIDS cohort (table 4.1) 
were also more likely to be men, have been previously diagnosed with tuberculosis, and been 
hospitalized during the previous two years.  All patients in the AIDS cohort were infected 
with HIV, while less than 5% of patients in the non-AIDS cohort patients tested positive for 
HIV. HIV-infected patients in the non-AIDS cohort were excluded from the final analysis. 
Most patients in the AIDS cohort were in advanced stages of HIV and thus extremely 
immunosuppressed. Of the 158 AIDS-cohort patients that we were able to test for CD4 
counts at the start of treatment, 112 or 71% had counts less than 100 cells/μL, 22 or 14% had 
counts between 100 and 200 cells/μL, and 24 or 15% had counts greater than 200 cells/μL.  
Among the 591 patients who entered our study with culture-positive tuberculosis, 100 
or 17% were multi-drug resistant, 27 or 5% were mono-resistant to rifampicin, and 42 or 7% 
were mono-resistant to isoniazid. Mono-resistance to isoniazid was significantly more 
common in the non-AIDS cohort, while multi-drug resistant TB was significantly more 
common in the AIDS cohort (table 4.2(a)). The predominant genotypes of MDR-TB in both 
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study cohorts at the start of DOTS treatment (figure 4.4a) were T1 (36/97 or 37%) and Lam9 
(26/97 or 27%). T1 was equally present in both the AIDS and non-AIDS cohorts (χ2=0.94, p-
value=0.33). Lam9 was more common in the AIDS cohort (χ2=4.02, p-value=0.04). 
Of 355 patients who began DOTS treatment with drug-susceptible TB and had 
follow-up data, 25 or 7% acquired multi-drug resistance, 3 or 1% acquired rifampicin mono-
resistance, and 10 or 3% acquired isoniazid mono-resistance. Patients in the AIDS cohort 
acquired multi-drug resistance at a higher rate than patients in the non-AIDS cohort (table 
4.2(b)). We found no group difference in the rate of acquiring mono-resistance to isoniazid or 
rifampicin.  
Our analysis of strain conversion status revealed that 92% (11/12) of AIDS cohort 
patients and 92% (12/13) of non-AIDS cohort patients who acquired multi-drug resistance 
during DOTS treatment had developed primary multidrug resistance. 0% (0/12) of AIDS 
cohort patients and 8% (1/13) of non-AIDS cohort patients had developed secondary 
multidrug resistance. Conversion status was undetermined for 8% (1/12) of patients in the 
AIDS cohort due to insufficient quantity of sample. We found no cohort difference in the 
proportion of patients who developed secondary versus primary multidrug resistance 
(Fisher’s Exact test=1.00).   
Among those who acquired primary multi-drug resistant tuberculosis during DOTS 
treatment, we identified Lam9 in 55% (6/11) of AIDS cohort patients and 17% (2/12) of non-
AIDS cohort patients. Although Lam9 was more common among AIDS cohort patients who 
acquired MDR-TB during treatment (χ2=5.00, p-value=0.02), we found no difference in the 
risk of superinfection with Lam9 between AIDS cohort patients [Standardized Incidence 
Ratio (SIR): 1.63 (95% CI: 0.5 to 3.8] and non-AIDS cohort patients [SIR: 1.75 (95% CI: 0.4 
to 5.1)] after adjusting for the baseline risk of exposure to circulating MDR-TB strains.  
To evaluate whether patients in the AIDS cohort were being infected by the same 
Lam9 clone, we typed isolates collected from all MDR-TB patients using IS6110 RFLP band 
patterns. We identified 4 clusters and 25 unique clones. The largest clusters came from: 
Lam9 which was divided into one cluster of 29 isolates, and 4 unique clones; and, T1 which 
was divided into one cluster of 23 isolates, and 7 unique clones. All patients who acquired a 
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different strain of MDR-TB were infected with T1 or Lam9 “cluster” clones (figure 4.5). The 
remaining clustered isolates in our analysis accounted for 4 cases of MDR-TB, but did not 
include an acquired MDR-TB case. Using a sub-analysis of 12 MDR-TB isolates (i.e., 6 from 
baseline cases and 6 from acquired cases), we found that Lam9 and T1 “cluster” clones were 
also circulating within the non-AIDS cohort. We observed that 100% (4/4) of Lam9 isolates 
and 63% (5/8) of T1 isolates shared identical band patterns as “clustered” clones detected in 
the AIDS population.  
In order to identify factors that may have contributed to the epidemic clone of Lam9 
becoming predominant among HIV-infected patients, we conducted a univariate analysis 
among all patients with MDR-TB at the start of DOTS treatment. Table 4.3 shows that 
patients infected with the epidemic clone of MDR-TB were more likely to experience 
diarrhea as compared to patients infected with other clones of MDR-TB. The most useful 
factors for ruling “in” infection with the Lam9 epidemic clone among all patients with MDR-
TB included being underweight, shortness of breath, weight loss and having had prophylaxis 
for tuberculosis. 
 
4.5. Discussion 
Our prospective study showed that AIDS patients with drug-susceptible tuberculosis between 
1999 and 2005 were at greater risk of acquiring multi-drug resistance during DOTS treatment 
than non-AIDS patients, and that the majority of these patients were infected with a different 
multidrug resistant strain during treatment. Our findings support previous scientific evidence 
that DOTS can effectively prevent the development of drug-resistance among pan susceptible 
strains of M. tuberculosis 109. However, these results also suggest that malabsorption of anti-
tubercular drugs may be an unlikely cause of MDR-TB outbreaks in settings with a high 
prevalence of AIDS 38-43,54.  
Using DNA fingerprinting, we determined that the majority of AIDS patients who 
acquired multi-drug resistance were infected by just one strain (i.e., Lam9). While Lam9 was 
found to be circulating within both the AIDS and non-AIDS cohorts, it was more common 
among patients in the AIDS cohort both at the start and during DOTS treatment. Taken 
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together, these observations would tend to suggest a synergistic effect between 
immunosuppression and infection with particular clones of MDR-TB. However, further 
analysis revealed that when the baseline prevalence of MDR-TB strains was adjusted for, 
AIDS and non-AIDS patients shared the same risk of superinfection with Lam9.  
Identifying why AIDS patients had such a high baseline prevalence of Lam9, was a 
major issue in our study. Our regression models of patients with MDR-TB at the start of 
DOTS treatment, revealed an unexpected association between the risk of infection with the 
epidemic clone of Lam9 and diarrhea. Although the mechanisms underlying this association 
are purely speculative, an increased susceptibility for acquiring MDR-TB following infection 
with other diarrhea associated diseases might explain our results. The gastrointestinal tract 
has long been recognized as the most common site for opportunistic infections among HIV-
infected patients 45 110, and humoral immune responses against diarrhea-associated parasites 
are thought to favor infection with M. tuberculosis and HIV 111 112 113. We were unable to test 
this hypothesis in our study since we only evaluated patients for the presence of an 
underlying medical conditions (that included diarrhea), rather than detailed information 
specifically concerning diarrhea. However, future epidemiological studies on tuberculosis 
and diarrhea might be designed to examine the role that infection with different diarrhea-
associated parasites has on the risk of infection and the development of active tuberculosis. 
We also found that administration of isoniazid prophylaxis was a useful factor for 
“ruling in” infection with the Lam9 epidemic clone of MDR-TB. It is feasible to assume that 
mono-isoniazid therapy of latent tuberculosis or undetected active tuberculosis could have 
partially contributed to the outbreak of MDR-TB. Between 52% and 63% of HIV-positive 
individuals with active tuberculosis have the extra pulmonary form, and approximately 30% 
of HIV-infected patients have latent tuberculosis 3 114. Although we found no difference in 
risk factors for infection with tuberculosis, namely past history of tuberculosis, risk of known 
contact with TB, hospitalization during the previous two years, or cavitation (a marker for 
past tuberculosis infection) between patients with Lam9 versus other MDR-TB strains at 
baseline, our study may not have had sufficient statistical power to detect these associations. 
Still, our results highlight the need to rule out all forms of tuberculosis (not just pulmonary 
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tuberculosis) and provide the same level of patient support found in DOTS programs, when 
administering prophylaxis to HIV-infected patients. 
In terms of strain distribution, we noted that patients in the AIDS cohort who resided 
in more geographically dispersed regions, had more strains in common than patients in the 
non-AIDS cohort. Although transmission of tuberculosis rarely occurs over large 
geographical distances, this is often due to the fact that individuals tend to socialize within 
rather than outside their own community 115. Several studies have noted that TB clusters may 
be more closely linked to social networks rather than geographical location per se 116,117. At 
the time that data collection for this study took place, HIV infection was extremely 
uncommon in the general population of Peru and largely restricted to marginalized 
populations such as injection drug users, men who have sex with men and commercial sex 
workers 118. Consequently, the paradoxical differences in strain distribution between both 
study cohorts may have been a reflection of socialization practices which led to infection 
with M. tuberculosis at the time of HIV infection.  
Several methodological issues should be considered when reviewing our results. First, 
while our study identified one particular strain of M. tuberculosis (i.e., Lam 9) that was 
strongly associated with the MDR-TB outbreak in the AIDS cohort, we do not believe that 
this represented a strain effect. Nosocomial outbreaks in Argentina and New York City 
among HIV-infected populations during the early 1990’s had been caused by M and W 
strains, respectively 89 119, suggesting that a co-factor other than strain type, may be 
responsible for MDR-TB outbreaks.  
Second, although our study had a large sample size relative to other previously 
published studies on MDR-TB and AIDS 109,120,121, the statistical power for our regression 
analysis remained low. We estimate that in order to detect a 50% increase in risk among 
MDR-TB patients infected with Lam9 using an alpha level of 0.05 and a beta level of 0.80, 
we would have needed 279 Lam9 MDR-TB cases and a total of 1116 MDR-TB patients, 
using a ratio of three controls per case. Enrolling this number of subjects would probably not 
be feasible given that MDR-TB is relatively rare in Peru [i.e. In 2006, 96 patients or 5.3% of 
all new tuberculosis cases were identified as MDR-TB 34] and the molecular dynamics of M. 
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tuberculosis could change over a span of one or two decades particularly if the tuberculosis 
cases in our study represented recent rather than reactivated forms of the disease 122. To 
remedy this problem, we included in our study analysis both the 90 and 95 percent 
confidence interval, when a cell was less than 5 patients. Still, our study may have failed to 
detect certain true associations. 
Third, our study was unable to differentiate between acquired MDR-TB cases due to 
super-infection versus undetected polyclonal infection at the start of DOTS. It has been 
hypothesized that for patients infected by multiple strains of M. tuberculosis, MDR-TB may 
be allowed to grow uninhibited when first-line treatment suppresses non-MDR-TB strains 
123,124. These MDR-TB strains would only be detected later on during DOTS (figure 4.6a), 
thus giving the appearance of a super-infection with MDR-TB. A sub-analysis of 25 culture-
positive samples obtained from our study participants at the start of DOTS revealed that 16% 
shared more than one spoligotype at testing: a number that is within previously reported 
ranges of 10 to 19% 123-126. If patients were infected with a new strain of MDR-TB during 
DOTS, it is also difficult to determine where transmission occurred at the DOTS clinic or 
within the general community since most study participants were outpatients. Still, if 
transmission did occur at the clinic, one option would be to treat MDR-TB patients separately 
from patients with drug-susceptible TB [e.g., in different rooms of a clinic or, if this is not 
possible, at different times of day (morning vs. afternoon)] 
Fourth, all study participants were unaware of their drug-susceptibility status and 
strain of infection, at the time that patient interviews were conducted, thus minimizing the 
possibility of selection or recall bias. Additionally, selective recall of diarrheal status was 
minimized by the fact that our questionnaire asked patients whether they had one of six 
underlying medical conditions (i.e., diabetes, diarrhea, cardiopathy, renal disease, cancer, 
liver disease and/or other), rather than diarrhea alone.  
In conclusion, most AIDS patients with drug-susceptible pulmonary tuberculosis who 
acquired multidrug resistance during DOTS treatment in Lima, Peru had been infected with a 
different MDR-TB strain rather than developed secondary drug resistance. While this strain 
was more common among patients in the AIDS cohort, the risk of super-infection did not 
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differ between AIDS and non-AIDS patients, suggesting that another factor (possibly 
associated with diarrhea) may be contributing to the strain’s high prevalence among AIDS 
patients. 
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4.6. Figures and Tables 
 
Figure 4.1.   Timeline for data collection and analysis  
 
Figure 4.2.  Study flow chart 
 
Figure 4.3.   Map showing patients’ place of residence in Metropolitan Lima, by  
study cohort 
 
Figure 4.4.   Frequency distribution of genotypes in sputum isolates from patients  
with multi-drug resistant Mycobacterium tuberculosis  
 
Figure 4.5.   IS6110 RFLP hybridization pattern for Lam 9 and T1 cluster clones of 
multi-drug resistant Mycobacterium tuberculosis identified in Lima, 
Peru between 1999 and 2005. 
 
Figure 4.6. Illustration of different types of drug-resistance acquired during DOTS 
 
 
 
Table 4.1.  Baseline characteristics of 591 culture-positive patients with  
 complete drug-susceptibility data at the start of DOTS treatment in  
 Lima, Peru between 1999 and 2005. 
 
Table 4.2. (a) Proportion of patients with drug-resistant tuberculosis at the start of 
DOTS treatment for tuberculosis 
 
(b) Incidence rate of acquiring drug-resistance during DOTS treatment 
for tuberculosis 
 
Table 4.3.   Factors associated with infection with the epidemic clone among 91  
 patients with MDR-TB at the start of DOTS treatment in Lima, Peru 
between 1999 and 2005 
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FIGURE 4.3. Map showing patients’ place of residence in Metropolitan Lima, by study 
cohort 
 
 
 
 
Non-AIDS Cohort 
AIDS Cohort 
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FIGURE 4.5.  IS6110 RFLP hybridization pattern for Lam 9 and T1 cluster clones of 
multi-drug resistant Mycobacterium tuberculosis identified in Lima, Peru between 1999 
and 2005.  
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TABLE 4.1. Baseline characteristics of 591 culture-positive patients with complete 
drug-susceptibility data at the start of DOTS treatment in Lima, Peru between 1999 
and 2005. 
 
 
 
 
 
 
 
 
Characteristic 
Non-AIDS 
Cohort 
(n=386) 
AIDS Cohort 
(n=205) 
Age in years, median (IQR) 25 (20 – 33) 31 (26 – 37) 
Male, n (%) 222 (58) 147 (72) 
HIV-positive, n (%) 13 (3) 205 (100) 
Previously diagnosed with tuberculosis, n (%) 60 (15) 98 (48) 
Hospitalized during the previous two years, n (%) 51 (13) 88 (43) 
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TABLE 4.4.  Association between grade of smear status and infection with the Lam9 
epidemic clone among 91 patients with MDR-TB at the start of DOTS treatment in 
Lima, Peru between 1999 and 2005. 
 
 
 
Grade  
of Smear 
Status 
No. of patients 
infected with 
epidemic clone 
 
 
Likelihood Ratio 
 
Univariate 
Odds Ratio  
(95% 
Confidence 
Interval) 
 
 
P 
Value 
Positive Negative Positive Test (95% 
Confidence 
Interval) 
Negative Test  
(95% Confidence 
Interval) 
0 3 16 1.0 1.0 1.0 - 
1+ 8 28 1.41 
(0.4 – 4.7) 
1.08 
(0.8 – 1.4) 
1.52 
(0.4 – 6.6) 
0.57 
2++ 4 8 2.11 
(0.6 – 7.8) 
1.26 
(0.8 – 2.0) 
2.67 
(0.5 – 15) 
0.26 
3+++ 8 17 2.03 
(0.6 – 6.6) 
1.24 
(0.9 – 1.7) 
2.51 
(0.6 – 11) 
0.23 
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CHAPTER 5. 
Prevalence and factors associated with shedding of mycobacteria in 
the stool of AIDS patients at different stages in the natural history of 
tuberculosis 
 
Knowledge Generation 
Based on our observation in study #1, that gastrointestinal-related factors were associated with AIDS 
patients being superinfected with particular clones of MDR-TB during DOTS, for our second study 
we characterized the prevalence and factors associated with gastrointestinal colonization with 
tuberculosis among HIV/AIDS patients. 
 
 
 
5.1. Study Summary 
 
Background: We characterized the prevalence and factors associated with shedding viable 
mycobacteria in stool, among AIDS patients with tuberculosis. Methods: We identified two 
groups of AIDS patients at different stages in the natural history of tuberculosis [n=30 in the 
Early-stage cohort; n=69 in the Late-stage cohort]. Sputum and stool samples were collected 
from all patients at study entry. Patients in the late-stage cohort were also interviewed, had 
physical exams, and were followed-up during Directly Observed Therapy Short-course for 
tuberculosis. Results: Culture positive mycobacteria were isolated from the stool of 45% 
(13/29) of pulmonary tuberculosis patients in the early-stage cohort and 77% (35/46) of 
pulmonary tuberculosis patients in the late-stage cohort. In both cohorts, shedding was more 
common among those with smear-positive disease (χ2=2.04, p=0.04), and rarely occurred in 
the absence of pulmonary tuberculosis, even when patients were diagnosed with extra-
pulmonary tuberculosis (χ2=24.1, p<0.001). Hospitalization during the previous two years 
was a protective factor for shedding, even after adjusting for patients’ history of tuberculosis 
(Odds Ratio: 0.14, 95% Confidence Interval: 0 to 0.7). Conclusion: Shedding of viable 
mycobacteria in stool was common among AIDS patients with pulmonary tuberculosis, 
particularly among those in the later stages of the disease. Previous hospitalization was a 
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protective factor against colonization suggesting that treatment for another opportunistic 
infection may provide indirect health benefits for HIV-infected individuals who develop 
tuberculosis later on. 
 
5.2. Background: 
Tuberculosis is the leading causes of morbidity and mortality among HIV-infected 
individuals. However, the gastrointestinal tract remains the most common site of 
opportunistic infections among HIV-infected individuals 45 110,127. The elevated risk of 
infection at this site is often attributed to the gastrointestinal tract being a major site of HIV 
replication. This eventually causes a depletion of CD4 cells within the lamina propia of the 
stomach and gastrointestinal tract making the person vulnerable to opportunistic infection 
110,127,128. HAART has helped to decrease the risk of gastrointestinal complications among 
these patients 110. Still, gastrointestinal disease continues to be a problem in developing 
countries where access to HAART may be limited. 
Despite a long standing recognition that low CD4 counts can lead to infection and the 
development of active tuberculosis, few studies have examined the prevalence of 
gastrointestinal colonization with mycobacteria among AIDS patients. Mycobacterium 
tuberculosis has long been recognized as an obligate aerobe that is only transmissible 
through air. However, the bacteria have also been known to survive the low pH high anoxic 
conditions found in the stomach 13,129-131. Several case studies have also reported isolating M. 
tuberculosis in the stool of children and adults with intestinal tuberculosis 132-135. 
Gastrointestinal tuberculosis may be an important issue among AIDS patients, since they are 
more likely to experience extra pulmonary tuberculosis and are at greater risk of developing 
disseminated forms of the disease during the later stages of active tuberculosis as compared 
to HIV-negative patients 6.  
In this study, we characterized the prevalence of viable mycobacteria in the stool of 
AIDS patients at different stages in the natural history of pulmonary tuberculosis; and 
identified risk factors for shedding mycobacteria among AIDS patients in the later stages of 
tuberculosis disease.  
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5.3. Methods: 
 
5.3.1. Study Setting: 
Data for this study was collected at the Infectious Disease Clinic of the Hospital Dos de 
Mayo between March 2002 and January 2004. During this time period, the hospital was the 
main referral center for HIV-infected individuals living in the greater metropolitan region of 
Lima, Peru. In 2003, the HIV-seropositivity level in Peru was estimated at 3.4 per 100,000 
persons 136, from which 50% of HIV-infected patients developed active tuberculosis during at 
least one point in their illness 94.  
 
5.3.2. Study Populations: 
We identified two groups of AIDS patients at different stages in the natural history of 
tuberculosis. The first group (Early-stage cohort) consisted of AIDS patients who were 
exhibiting respiratory symptoms at the time of study entry and diagnosed with pulmonary 
tuberculosis during our study. These patients were identified by screening consecutively 
enrolled HIV-infected patients who reported coughing during at least one week. The second 
group (Late-stage cohort) consisted of AIDS patients who were already diagnosed with 
tuberculosis (pulmonary or extra pulmonary form) at the time of study entry; and, were about 
to commence Directly Observed Therapy Short-Course (DOTS) as part of the Peruvian 
National Tuberculosis Control Program. None of the study participants in either cohort were 
receiving tuberculosis treatment at the time of study enrolment. Patients in the early-stage 
cohort were also eligible to participate in the late-stage cohort, if they were recommended 
for tuberculosis treatment. All study participants provided written informed consent. 
Institutional Review Boards at the Johns Hopkins Bloomberg School of Public Health, 
Hospital Dos de Mayo and A.B. PRISMA approved the original study protocols. 
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5.3.3. Data Collection: 
For the early-stage cohort, patients with a productive or wet cough were asked to provide 
two sputum, one stool and one urine sample. Sputum samples were collected on consecutive 
days with all samples being collected within a one-week period. Patients with a non-
productive or dry cough were asked to provide one sputum and one stool sample on the same 
day. Sputum was induced using a hypertonic saline solution. For the late-stage cohort, we 
asked patients to provide one sputum and one stool sample at the time of study enrollment 
(day 0) as well as day 1, month 1, month 2, month 4, month 6 of DOTS treatment, and once 
at the end of treatment. They were also measured for weight in kilograms and height in 
meters; observed for the presence of scars from a Bacille-Calmette Guerin (BCG) vaccine; 
had blood samples collected for CD4 counts; and interviewed for socio-demographic 
characteristics, clinical manifestations and history of exposure to tuberculosis (please refer to 
Appendix 4). Information on diarrheal status was not available for this study. 
 
5.3.4. Laboratory Methods and Definitions: 
Sputum samples were tested for smear status using Auramine Smear Microscopy; culture 
status using Lowenstein-Jensen and Middlebrook 7h9 Broth (Difco, Detroit, Mich.); and 
drug-susceptibility status using the Microalamar Blue Assay (MABA) 101. Stool samples 
were tested for smear status using Auramine Smear Microscopy; and were then cultured 
using Lowenstein-Jensen, Middlebrook 7h9 Broth (Difco, Detroit, Mich.) and Middlebrook 
7h10 Agar (Difco, Detroit, Mich.). Drug-susceptibility status in stool samples was assessed 
using MABA, only when the matching sputum sample from a patient was culture-negative. 
We categorized samples as drug-resistant if the MABA Minimum Inhibitory Concentration 
(MIC) was greater than 0.25 µg/mL for rifampicin; 0.25 µg/mL for isoniazid; 5.0 µg/mL for 
ethambutol; and, 2.0 µg/mL for streptomycin 102. We classified a sample as drug-resistant if 
it was resistant to at least one drug; multi-drug resistant if it was resistant to both rifampicin 
and isoniazid; and culture-positive if tuberculosis was grown on at least one type of growth 
media. Patients had pulmonary tuberculosis if they produced at least one sputum sample that 
was culture-positive for tuberculosis. 
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For patients in the late-stage cohort, we conducted spoligotype DNA fingerprinting 
on the first culture-positive sputum sample collected from each patient. In order to determine 
whether the strain of tuberculosis found in sputum was the same as that found in stool, we 
identified and compared spoligotypes octal code numbers for seven pairs of sputum and stool 
samples. We identified strain genotypes for sputum samples by comparing each isolate’s 
spoligotype octal code number with those recorded in the SpolDB4 database 105. CD4 
lymphocyte counts were obtained from blood samples using the Manual CD4 Cell Count Kit 
(Coulter).  
 
5.3.5. Data Analysis: 
Using data from both the early and late-stage cohorts, we presented categorical variables as 
numbers with proportions; and, continuous variables as medians with inter-quartile ranges. 
We estimated the culture yield by dividing the number of samples from which we isolated 
culture-positive tuberculosis by the total number of samples tested; and time to culture-
positivity in days by subtracting the date on which growth in a particular culture-media was 
first observed from the date that the sample was inoculated. We tested for differences in 
paired means using T-test; differences in proportions using the McNemar’s χ2 test or, when a 
cell had less than 5 samples or patients, the Fisher’s Exact test; and the presence of trends 
using the χ2 test for trend. We summarized the extent of concordance and discordance 
between different types of diagnostic media per sample and different isolates per patient 
using Venn diagrams. We drew proportional Venn diagrams using Euclidian geometry, with 
the area of the circle representing the size of the population and the area of intersecting 
circles representing the degree of overlap between two or more populations.  
Using data from the late-stage cohort, we estimated the univariate odds ratio using 
exact logistic regression and the positive and negative likelihood ratio using standard formula 
for each clinical manifestation reported by patients 107. We asked patients regarding the 
presence (or absence) of the following clinical manifestations: cough, productive cough, 
fever, shortness of breath, hemoptysis, weight loss, loss of appetite, night sweats, and fatigue. 
We also identified risk factors for shedding mycobacteria in stool using an exact logistic 
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regression model. Our multivariate model included the following covariates: age in years, sex 
[male or female], Body Mass Index in kilograms per meters2, CD4 counts in cells per µL, 
receiving antiretroviral treatment [yes or no], history of prophylaxis for tuberculosis [yes or 
no]; presence of BCG scar [yes or no/not not known], previous diagnosis with tuberculosis 
[yes or no/unknown], known contact with a tuberculosis patient [yes or no/unknown], 
previously worked or lived in a prison/shelter [yes or no], and hospitalized during the 
previous two years [yes or no]. All statistical analysis were conducted using STATA 
(College Station, TX). 
 
5.3.6. Role of the Funding Source: 
The funding source had no role in study design, data collection, data analysis and data 
interpretation, writing of the manuscript or the decision to publish. 
 
5.4. Results: 
From 2002 to 2004, we screened 473 consecutive respiratory symptomatic patients for 
pulmonary tuberculosis (Early-stage cohort), and enrolled 106 patients referred to the 
Peruvian National Tuberculosis Control Program for the treatment of tuberculosis (Late-
stage cohort). Figure 5.1 illustrates the flow of study participants throughout our study. 403 
or 85% of patients in the early-stage cohort and 72 or 68% of patients in the late-stage 
cohort provided both a sputum and stool sample for testing. 12 patients in the early-stage 
cohort and 3 patients in the late-stage cohort provided either contaminated or insufficient 
volumes of samples to be tested, and were thus excluded from our analysis. 
 
5.4.1. Growth characteristics of sputum, stool and urine samples 
We isolated culture-positive tuberculosis in 20% (115/589) of sputum samples, 8% (46/551) 
of stool samples, and less than 1% (1/124) of urine samples. Of these, 52% (48/115) of 
sputum isolates, 14% (20/46) of stool isolates, and 0% (0/1) of urine isolates were smear-
positive for acid-fast bacillus. Sputum samples were more likely to be smear-positive than 
stool samples from the same patient (χ2=12.6, p<0.001). The culture yield from sputum 
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samples was the same regardless of the type of media used (χ2=0.50, p=0.73). For stool 
samples, Middlebrook 7h10 agar yielded the same quantity of culture-positive isolates as 
Lowenstein-Jensen (χ2=3.27, p=0.12) but fewer culture-positive isolates than Middlebrook 
7h9 broth (χ2=10.89, p=0.001). We found no difference in the culture yield of stool samples 
using Lowenstein-Jensen versus Middlebrook 7h9 broth (χ2=3.77, p=0.09). We also found no 
difference in time to culture-positivity for sputum and stool samples grown on Lowenstein-
Jensen (t-test: 1.15, p=0.25). However, stool samples took longer to culture than sputum 
samples, when grown on Middlebrook 7h9 broth (t-test: 2.61, p<0.001).  
 
5.4.2. Patients characteristics for shedding mycobacteria in stool 
Of the total 460 patients who provided complete sputum and stool samples, 75 (16%) had 
culture-positive sputum, and 49 (11%) had culture-positive stool (Table 5.1). 64% (48/75) of 
patients with culture-positive sputum also had culture-positive stool. Figure 5.3 shows that 
shedding rarely occurred in the absence of pulmonary tuberculosis, even when patients in the 
late-stage cohort were diagnosed with extra-pulmonary tuberculosis. Of the 75 patients with 
pulmonary tuberculosis, we identified mycobacteria in the stool of 72% (21/29) of patients 
with high-grade (3+) smear-positive disease; 100% (5/5) with medium-grade (2+) smear-
positive disease; 62% (10/16) with low-grade (1+) smear-positive disease; and, 48% (12/25) 
with smear-negative (0-) disease. While patients with smear-positive pulmonary tuberculosis 
were more likely to shed mycobacteria in stool than those with smear-negative disease 
(χ2=2.04, p=0.04), we found no trend in stool shedding by grade of smear status (χ2=6.50, 
p=0.09). A sub-analysis of paired sputum and stool samples from seven patients in the late-
stage cohort showed that each pair of samples had matching spoligotype octal code numbers. 
 We found no difference in shedding (Fisher’s Exact Test=0.45, p=0.25) between 
pulmonary tuberculosis patients in the early stage cohort with productive (33% or 4/12) and 
non-productive cough (53% or 9/17). However, stool shedding was more common among 
pulmonary tuberculosis patients in the late-stage cohort (χ2=7.54, p=0.006), with 45% 
(13/29) of pulmonary tuberculosis patients in the early-stage cohort and 77% (35/46) of 
pulmonary tuberculosis patients in the late-stage cohort had culture-positive stool. Patients in 
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the late-stage cohort were also more likely to have smear-positive pulmonary tuberculosis as 
compared to those in the early-stage cohort (χ2=19.65, p<0.001).  
 The predominant strains of pulmonary tuberculosis among patients in the late-stage 
cohort with stool shedding were T1 (31%), H3 (17%) and T2 (11%). However, each strain 
was equally present among pulmonary tuberculosis patients who were not shedding [χ2 for 
T1: 2.17 (p=0.14), H3: 0.55 (p=0.46), and T2: 0.05 (p=0.83)]. Table 5.2 shows that patients 
in the late-stage cohort with gastrointestinal colonization were less likely to have been 
hospitalized during the previous two years, after adjusting for a patient’s history of 
tuberculosis. Table 5.3 shows that the most useful factors for identifying patients who may 
have been shedding included cough and loss of appetite. Of the 33 patients in the late-stage 
cohort who were followed-up during DOTS and had culture-positive stool, 28 (85%) stopped 
shedding by the first month of treatment. The remaining 5 (15%) patients who did continue 
to shed were all infected with rifampicin-resistant tuberculosis, and thus may not have been 
responding to DOTS. 
 
5.5. Discussion 
Our cross-sectional study revealed that shedding of viable mycobacteria in stool was 
common among AIDS patients with pulmonary tuberculosis, particularly amongst those in 
the later stages of the disease. Although stool shedding was more prevalent in pulmonary 
tuberculosis patients with smear-positive disease, it rarely occurred in the absence of 
pulmonary tuberculosis even when patients were diagnosed with extra pulmonary disease. 
Using spoligotype data on a subset of paired sputum and stool samples, we identified that the 
strain of M. tuberculosis isolated from a patient’s sputum was identical to the strain isolated 
in their stool.  
Taken together, these results support the hypothesis that when M. tuberculosis is 
swallowed, the bacteria may remain viable in the gastrointestinal tract and eventually be shed 
in stool. However, it is unclear whether our study results represented a unique phenomenon 
to AIDS patients in Lima, Peru or immunosuppressed patients as a whole. At the time that 
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data was collected, the AIDS population were undergoing an outbreak of MDR-TB with one 
particular clone of M. tuberculosis; a clone that was associated with diarrhea.  
If shedding is a common event, the high prevalence of viable tuberculosis in patients’ 
stool raises the question as to whether non-airborne transmission of M. tuberculosis may be 
possible in areas with a high prevalence of AIDS. It has long been established that 
transmission of other mycobacteria species may occur through water supply systems, 
contaminated food and wastewater 137-141. If the same is true for M. tuberculosis, then 
currently recommended health strategies that only target airborne modes of tuberculosis 
transmission (e.g. irradiation of air ducts with ultraviolet light) could be less effective in high 
AIDS-burden settings. These findings also highlight the need to diagnose and treat patients 
with pulmonary tuberculosis as quickly as possible, regardless of whether they have 
productive cough or not. 
We did find that hospitalization during the previous two years was a protective factor 
against shedding of mycobacteria in stool, even after adjusting for patients’ previous history 
of tuberculosis. Although the reasons for this link are unclear, hospitalization and previous 
residence in a prison or shelter may have been acting in our study as markers for access to 
health care.  In particular, several studies have suggested that when humoral immune 
responses against other diarrhea-associated parasites are induced, individuals may be at 
increased risk of infection with M. tuberculosis 111 112 113. Rapid detection and administration 
of anti-parasitic treatment could prevent this process from occurring. However, additional 
research will be needed in order to clarify these issues since study participants were not 
evaluated for diarrhea in this study. 
Our results showed that shedding was more common among patients in the later 
stages of pulmonary tuberculosis. One explanation for these results is that smear-positive 
disease was more common among patients in the later stages of pulmonary tuberculosis. 
Conversely, our regression analysis of risk factors for shedding also revealed that cough and 
loss of appetite were useful predictors for identifying patients who may be shedding. 
Although our study screened AIDS patients for respiratory symptoms during the previous 15 
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days, loss of appetite was not included in our screening criteria. The prevalence of shedding 
among patients in this cohort may have thus been underestimated. 
The identification of mycobacteria in stool may have important implications for 
developing tuberculosis diagnostics, particularly among individuals who exhibit non-
productive cough. Invasive procedures are often needed to extract sputum from patients with 
a dry cough. Such procedures can include nasal-gastric aspiration or inducing sputum with 
hypertonic solutions 142. Examination of stool rather than sputum could limit the use of such 
invasive procedures, facilitating the diagnostic process in turn. 
Several additional study limitations should be considered. First, our results should not 
be generalized beyond persons with AIDS. As previously mentioned, the gastrointestinal 
tract represents a major site of HIV replication and CD4 depletion 110,127,128. Consequently, 
the pathophysiology of gastrointestinal colonization with mycobacteria may differ between 
immunosuppressed and otherwise healthy patients. Second, our study may have failed to 
detect certain factors associated with shedding due to the small sample size. Using an alpha 
of 0.05 and a beta of 0.80, we estimate that the lowest odds ratio that our model could detect 
was ≤0.60 or ≥4.6. Finally, we refer to culture-positive samples in stool as mycobacteria 
rather than M. tuberculosis since our study genetically verified the presence of M. 
tuberculosis only in a subset of stool samples. All culture-positive sputum samples were 
tested using spoligotype. 
In conclusion, shedding of mycobacteria in stool was common among AIDS patients, 
but rarely occurred in the absence of pulmonary tuberculosis. Cough and loss of appetite 
were useful predictors for identifying patients who might be shedding. Previous 
hospitalization was a protective factor against colonization, suggesting that treatment for 
another disease may provide indirect health benefits for HIV-infected patients who develop 
tuberculosis later on. 
59 
 
 
5.6. Figures & Tables 
 
 
 
Figure 5.1.  Flow of patients through study 
  
Figure 5.2. Proportional Venn diagram showing the type of culture medium used to 
identify tuberculosis in sputum and stool isolates. 
 
Figure 5.3.  Proportional Venn diagram showing the type of isolate used to identify patients 
with culture-positive tuberculosis 
 
 
 
 
Table 5.1.  Number and proportion of AIDS patients with culture-positive 
Mycobacterium tuberculosis in sputum, stool and urine isolates. 
 
Table 5.2.  Diagnostic validity of clinical manifestations for identifying DOTS patients 
who were shedding mycobacteria in stool 
 
Table 5.3.  Risk factors for shedding mycobacteria in stool among 65 patients in the later 
stage of tuberculosis in Lima, Peru between 1999 and 2005. 
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FIGURE 5.3. Proportional Venn diagram showing the type of isolate used to identify patients 
with culture-positive tuberculosis 
 
(a) “Early-Stage” Cohort (Total number of Patients= 391) 
 
  
 
 
 
 
 
 
Pr {Shedding in stool | Pulmonary tuberculosis}: 
 
45% (13/29) 
Pr {Shedding in stool | No pulmonary tuberculosis}: 0.3% (1/362) 
Pr {Pulmonary tuberculosis | Shedding in stool}: 93% (13/14) 
 
 
(b) “Late-stage” Cohort (Total number of Patients= 69) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pr { Shedding in stool | Pulmonary tuberculosis}: 
   
77% (35/46) 
Pr {Shedding in stool | No pulmonary tuberculosis}     0% (0/23) 
Pr {Pulmonary tuberculosis | Shedding in stool}: 100% (35/35) 
Sputum Samples 
n=29 patients Stool Samples 
n=14 patients 
13 16 
 
1 
Sputum Samples 
n=46 patients Stool Samples 
n=35 patients 
35   11 
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TABLE 5.1. Number and proportion of AIDS patients with culture-positive tuberculosis in 
sputum, stool and urine isolates. 
 
 
 
 
Type of Isolate 
 
Early-stage Cohort 
 
 
Late-stage Cohort 
n (%) 
 
 
Overall 
n (%) 
 “Wet Cough” 
n (%) 
“Dry Cough” 
n (%) 
Overall 
n (%) 
Sputum 12 (9.7) 17 (6.4) 29 (7.4) 46 (67) 75 (16) 
Stool 4 (3.2) 10 (3.7) 14 (3.6) 35 (51) 49 (11) 
Urine 1 (0.8) - - - - 
Sputum or Stool 12 (9.7) 18 (6.7) 30 (7.7) 46 (67) 76 (17) 
Total Number  of AIDS Patients 124 (100) 267 (100) 391 (100) 69 (100) 460 (100) 
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TABLE 5.3. Risk factors for shedding tuberculosis in stool among 65 patients in the 
later stage of tuberculosis in Lima, Peru between 1999 and 2005 
 
 
* CD4 counts could not be measured below 30 cells/μL. We thus substituted all values equal to “<30” by 29 in our model. 
 
 
Characteristic 
No. of Patients 
Not Shedding 
TB 
(n=31) 
No. of Patients 
Shedding  
TB 
(n=34) 
Unadjusted 
Odds Ratio 
(95% CI) 
Adjusted 
Odds Ratio 
(95% CI) 
Age in years 29 (25 – 38) 31 (27 – 33) 0.98 (0.9 – 1.1) 1.06 (0.9 – 1.2) 
Gender 
 Female 
 Male 
 
8 
23 
 
5 
29 
 
Ref 
2.01 (0.6 – 7.0) 
 
 
Ref 
5.82 (0.9 – 36) 
Body Mass Index  
    in kilograms per meters2 
19.2 (18 – 21) 18.6 (17 – 20) 0.79 (0.6 – 1.0) 0.89 (0.6 – 1.2) 
CD4 Count in cells/μL <30* (<30 – 68) <30 (<30 – 40) 0.99 (0.9 – 1.0) 0.99 (0.9 – 1.0) 
Receiving anti-retroviral treatment 
 No 
 Yes 
 
22 
9 
 
29 
5 
 
Ref 
0.42 (0.1 – 1.4) 
 
Ref 
0.50 (0.1 – 2.7) 
Past prophylaxis for tuberculosis 
 No 
 Yes 
 
13 
18 
 
13 
21 
 
Ref 
1.17 (0.4 – 3.2) 
 
Ref 
1.16 (0.2 – 6.6) 
Presence of BCG Scar 
 No/Not known 
 Yes 
 
6 
25 
 
9 
25 
 
Ref 
0.66 (0.2 – 2.2) 
 
Ref 
0.91 (0.2 – 4.3) 
Previously diagnosed with tuberculosis 
 No/ Not known 
 Yes 
 
21 
10 
 
24 
10 
 
Ref 
0.88 (0.3 -  2.5) 
 
Ref 
0.94 (0.2 – 5.5) 
Known contact with tuberculosis case 
 No/Not known 
 Yes 
 
22 
9 
 
22 
12 
 
Ref 
1.33 (0.5 – 3.8) 
 
Ref 
2.25 (0.5 – 11) 
Previously in prison/shelter 
 No 
 Yes 
 
22 
9 
 
33 
1 
 
Ref 
0.07 (0 – 0.6) 
 
Ref 
0.15 (0 – 2.4) 
Hospitalized during the previous two 
years 
 No 
 Yes 
 
17 
14 
 
27 
7 
 
Ref 
0.32 (0.1 – 0.9) 
 
Ref 
0.14 (0 – 0.7) 
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CHAPTER 6.  
Screening HIV-infected patients for pulmonary tuberculosis using 
the Microscopic Observation Drug Susceptibility (MODS) assay: A 
pilot study 
 
Knowledge Integration/Technology Transfer 
Our previous two studies illustrated the importance of screening HIV/AIDS for pulmonary 
tuberculosis regardless of whether they had productive or non-productive cough. In light of this data 
and the potential for nosocomial transmission of pulmonary tuberculosis among AIDS patients, in the 
following study we evaluated the utility of MODS for culture-based screening of hospitalized HIV-
infected patients. 
 
 
6.1. Study Summary 
Background: To examine the clinical utility when using the Microscopic-Observation Drug-
Susceptibility (MODS) assay to screen hospitalized HIV-infected patients for pulmonary 
tuberculosis. Methods: Consecutive newly hospitalized HIV-positive patients not previously 
diagnosed with tuberculosis (n=150) at two public hospitals in Lima, Peru, were recruited 
and prospectively screened for pulmonary tuberculosis using clinical assessment, chest 
radiography and sputum smear microscopy. Sputum and/or gastric samples were cultured for 
Mycobacterium tuberculosis using MODS, Lowenstein-Jensen and automated MbBacT. 
Results: We found that 19% (28/150) of patients had pulmonary tuberculosis. Screening all 
admissions with sputum microscopy would have detected 39% (95%CI: 32-47) of patients 
with tuberculosis. Standard diagnostic criteria identified 32% (95%CI: 16-52) of patients 
with tuberculosis. Screening all patients using MODS correctly identified 96% (95%CI: 82-
100) of patients with tuberculosis, and provided concurrent drug-susceptibility results.  
Alternatively, targeting MODS testing to the 63% (95/150) of patients who were sputum 
smear-positive or smear-negative with clinically suspicious symptoms for tuberculosis, 
detected 93% (95%CI: 77-100) of patients with pulmonary tuberculosis, with 93% (14/15) of 
these cases being identified within two weeks of admission. Conclusion: Sputum smear-
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negative tuberculosis was common in newly hospitalized HIV-positive patients. Targeted 
culture-based screening with universal drug-susceptibility testing using MODS accurately 
and rapidly detected these cases. 
 
6.2. Background 
Globally, tuberculosis is the most common opportunistic infection affecting HIV-infected 
individuals, and can be particularly difficult to control for in hospitals caring for AIDS 
patients in resource-limited settings. Although nosocomial transmission to health-care 
workers and other susceptible patients can be prevented by early case detection and 
administration of effective drug therapy 87,143,144, diagnosing HIV-infected patients with 
pulmonary tuberculosis is an important challenge. HIV modifies the typical clinical 
presentation of tuberculosis, decreasing the diagnostic sensitivity of chest radiographs and 
sputum microscopy 22,23.   
In developing countries, where 95% of tuberculosis cases occur, diagnosis is further 
complicated by the limited availability of sensitive culture-based laboratory diagnostics 7. 
Barriers to using these tests include complexity, high capital and unit costs, and prolonged 
test duration 19,145. These diagnostic difficulties increase morbidity and mortality, and permit 
continuing tuberculosis transmission in a hospital setting 35. Modeling dynamics of 
tuberculosis transmission also suggest that improving diagnostic capability for tuberculosis 
among adult populations with a high HIV prevalence may reduce tuberculosis prevalence and 
mortality in the general community by approximately 20% 145.  
The World Health Organization has identified the development of rapid, sensitive, 
and affordable diagnostic tools for tuberculosis detection as a research priority 146,147. In 
recent years, the non-proprietary Microscopic-Observation Drug-Susceptibility (MODS) 
technique has been shown to detect Mycobacterium tuberculosis and its drug-susceptibility 
status in sputum samples more rapidly and efficiently than current standards of diagnosis yet 
at one-tenth the cost ($2) of gold-standard rapid assays 60,61,63,64,69.   
In this paper, we examine how well the laboratory performance of MODS for 
detecting tuberculosis in sputum samples translates into clinical usefulness when screening 
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hospitalized HIV-infected patients for active pulmonary tuberculosis disease. Firstly, we 
evaluate how screening hospitalized patients using the standard diagnostic criteria of sputum 
microscopy, symptom review and chest radiography, compares with an alternative approach 
of using MODS to screen all patients. Second, considering the need for immediate diagnosis 
and the limited resources that exist in most high HIV-TB burden settings, we analyze 
whether MODS screening could be targeted to pre-selected sub-groups of patients. Finally, in 
order to determine the wider generalizability of these results we model the effect that 
tuberculosis prevalence would have on the diagnostic efficiency of targeting screening using 
MODS. 
 
6.3. Study Population & Methods 
The study was conducted at two large public hospitals (Hospital Arzobispo Loayza and 
Hospital Hipolito Unanue) in Lima, Peru, between March 2003 and June 2004 as part of an 
operational evaluation of MODS 63. Regardless of clinical diagnostic suspicions, all adult 
(≥18 years) admissions to hospital who were known to be HIV-infected were consecutively 
recruited. Patients unwilling or unable to give consent or already diagnosed with tuberculosis 
were excluded. Patients who provided written informed consent underwent chest 
radiography, venesection for CD4 count, and an interview recording demographic 
characteristics, medical history, and tuberculosis-associated risk factors (please refer to 
Appendix 5). 
 
6.3.1. Sample Testing:  
Two sputum samples were collected on consecutive days. Morning (pre-breakfast) gastric 
washings were obtained from patients who could not produce sputum. All samples were 
processed in the research laboratory at Universidad Peruana Cayetano Heredia as described 
148,149. Briefly, samples were decontaminated by the NaOH n-acetyl cysteine method and then 
tested for acid fast bacilli using auramine sputum smear microscopy, and cultured in parallel 
using Löwenstein-Jensen slants, automated MbBacT broth culture (Biomériux), and MODS 
technique. Culture-positive samples were tested for drug-susceptibility to isoniazid, and 
69 
 
 
rifampicin using MbBacT, Löwenstein-Jensen proportion method 63, MODS and the Micro-
Alamar Blue Assay (MABA), with discrepant results for drug-susceptibility tests being 
interpreted as previously described 102. Laboratory technicians were blinded to the results of 
other test methods. Results were reported to the attending physician for use in patient 
management. 
 
6.3.2. Definitions:  
A patient was classified as having pulmonary tuberculosis if M. tuberculosis was isolated 
from sputum in at least one culture media. An infectious disease specialist blinded to clinical 
and study data but aware that all patients were HIV-infected graded chest radiographs on a 
five-point scale. A radiograph was considered to be “consistent” with tuberculosis if it was 
graded as possible or likely tuberculosis (e.g. presence of pleural lesions, cavitation, 
infiltrates or hilar enlargement), and “not consistent” with tuberculosis if it was normal, 
minimally abnormal but not consistent with pulmonary tuberculosis in an HIV-positive 
person (e.g. hyperinflation), or clearly abnormal but with a definite diagnosis other than 
tuberculosis (e.g., known hydatid cyst) 150.  
Patients were considered at increased risk for tuberculosis if they had been previously 
treated for tuberculosis, been in contact with a known tuberculosis case, worked in a health 
care facility or worked/resided in a penitentiary. Patients were considered at risk for drug-
resistant tuberculosis if they had been previously treated for tuberculosis or been in known 
contact with an MDR-TB case. Patients were categorized as having constitutional symptoms 
of tuberculosis if they reported fever, night sweats or weight loss at the time of study entry; 
respiratory symptoms of tuberculosis if they experienced coughing; and, prolonged cough if 
they experienced coughing for the last 15 days or more. Patients with cough and at least one 
constitutional symptom of tuberculosis (i.e., fever, night sweats or weight loss) were 
categorized as having symptoms clinically suspicious of pulmonary tuberculosis. Standard 
diagnostic criteria refer to the use in these hospitals of clinically suspicious symptoms, 
sputum microscopy, and chest radiography for diagnosing pulmonary tuberculosis (figure 
6.1).  
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6.3.3. Statistical analysis:  
The number and proportion of HIV-infected patients who were identified with pulmonary 
tuberculosis were calculated for each screening strategy. Sensitivity and specificity with 95% 
confidence intervals (95%CI) were estimated for each screening factor 151. For both screening 
strategies that used MODS, we estimated the effect of tuberculosis prevalence on the proportion 
of patients who would need MODS assays. The footnote to Figure 6.3 defines the sensitivity 
and specificity parameters used in the model. Analysis was performed using STATA v7 (Stata 
Corp, College Station, TX, USA). All tests were two-sided and p-value<0.05 was considered to 
be the threshold for statistical significance. 
 
6.3.4. Ethics review:  
Institutional review boards at AB PRISMA (Peru), Universidad Peruana Cayetano Heredia 
(Peru), Hospital Arzobispo Loayza (Peru), Hospital Hipolito Unanue (Peru), Imperial College 
London (UK) and Johns Hopkins Bloomberg School of Public Health (USA) approved the 
study. 
 
6.4. Results 
6.4.1. Patient recruitment and characteristics:  
Between March 2003 and June 2004, 184 patients who met the entry criteria were identified 
at the two hospitals. Twenty-five of these individuals either died before study procedures 
could be initiated or were unwilling or unable to provide written informed consent. The 
remaining 159 eligible patients contributed a total of 296 samples: 267 were sputum and 29 
were obtained by gastric lavage. Subjects were excluded from analysis if: no sputum or 
gastric samples were collected for testing (n=2); if all sputum cultures were repeatedly 
contaminated by bacterial/fungal overgrowth in all cultures (n=1); or if chest radiographic 
information was missing (n=6, all were culture-negative by MODS, MbBacT and 
Löwenstein-Jensen). The study analysis was based upon the remaining 150 patients who 
provided 284 samples.  
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Table 6.1 shows the demographic, radiographic, clinical and risk factor data for this 
population. On admission, 67% (101/150) of patients reported cough, 75% (112/150) weight 
loss, 54% (81/150) fever, and 39% (59/150) night sweats. Ninety-three percent (139/150) of 
patients provided two samples on two separate days, the remainder provided only one 
sample. Ninety-four percent (141/150) of patients had a CD4 count ≤200 cells/μL, 89% 
(125/150) of patients had a CD4 count <100 cells/μL, and 69% (104/150) of patients had a 
CD4 count <50 cells/μL. Twenty-eight patients with culture-positive pulmonary tuberculosis 
were identified using Löwenstein-Jensen, MbBacT or MODS (18%). Seventy-nine percent 
(22/28) of tuberculosis patients had concordant culture-positive results by all three methods, 
11% (3/28) were culture-positive by MODS and either MbBacT or Löwenstein-Jensen, 3.6% 
(1/28) were culture-positive only by MbBacT, and 7.1% (2/28) were culture-positive only by 
MODS.  
 
6.4.2. Screening using Standard Diagnostic Criteria:  
Figure 6.1(a) shows that screening all patients with sputum smear microscopy only identified 
39% (95%CI: 32-47) of culture-positive patients. Alternatively, the policy of using smear 
microscopy and chest x-rays among patients with symptoms suspicious for tuberculosis, 
failed to identify 68% (95%CI: 48-84) of patients with tuberculosis, and falsely identified 2% 
(95%CI: 0-6) of patients as having tuberculosis (figure 6.1(b)). Table 6.1 shows that clinical 
suspicion (defined as any cough and at least one constitutional symptom) was the best 
predictor of tuberculosis. However, in general all clinical characteristics had poor reliability 
for identifying patients with pulmonary tuberculosis. 
 
6.4.3. Culture-based Screening using MODS:  
Figure 6.1(c) shows that by using MODS to screen all participants for pulmonary 
tuberculosis 96% (95%CI 82-100) of patients with pulmonary tuberculosis were identified. 
This includes 95% (95%CI: 74-100) of the patients with pulmonary tuberculosis who were 
misdiagnosed by standard diagnostic criteria. None of the hospitalized patients would have 
completed this screening process on the same day. MODS culture of the second sputum 
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sample from each smear-negative patient only contributed one additional tuberculosis 
diagnosis compared with the first MODS culture from each patient. Median days to detect 
patients with tuberculosis was 6 days (Interquartile Range (IQR): 6-8) for MODS, 15 days 
(IQR: 12-17) for MbBacT, and 28 days (IQR: 23-24) for Löwenstein-Jensen.  
Figures 6.1(d) and illustrates that targeting MODS testing to the 63% (95/150) of 
patients who were sputum smear-positive or smear-negative with clinically suspicious 
symptoms for tuberculosis, detected 93% (95%CI: 77-100) of patients with pulmonary 
tuberculosis and 100% (95%CI: 97-100) who were culture-negative. Although this type of 
targeted screening missed one patient with tuberculosis, 37% (55/150) fewer patients had to 
be tested with MODS, enabling them to complete screening on the same day. 
We evaluated the generalizability of these results to other settings by modeling the 
effect of tuberculosis prevalence on the number of MODS tests done, using each screening 
strategy. Figure 6.3 shows that targeted MODS screening would require significantly fewer 
MODS assays than universal MODS screening provided that the TB prevalence was lower 
than 70%.  
 
6.4.4. Drug Susceptibility Testing  
Fifty-four percent (15/28) of pulmonary tuberculosis patients had drug-resistant tuberculosis: 
18% (5/28) resistant to isoniazid; 3.6% (1/28) to rifampicin; 36% (10/28) to streptomycin; 
and 0% (0/28) to ethambutol. 3.6% (1/28) of patients had MDRTB. Targeting drug-
susceptibility testing to the 25% (38/150) of patients with recognized risk factors for MDR-
TB failed to identify 80% (4/5) of patients with isoniazid and/or rifampicin resistant 
tuberculosis and 93% (14/15) of all patients with drug resistance.  
 
6.5. Discussion 
In this group of unselected HIV-positive people admitted to hospital, undiagnosed pulmonary 
tuberculosis was common and usually missed by screening strategies based on sputum 
microscopy, symptoms and chest radiographs. In contrast, sputum culture with MODS was 
more reliable and provided rapid concurrent drug-susceptibility testing. MODS was most 
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efficient when restricted to patients who reported symptoms clinically suspicious for 
tuberculosis at the time of admission.  Mathematical modeling suggested that this increased 
efficiency from targeting MODS would be greatest in settings with lower tuberculosis 
prevalence.  
Previous studies have shown that duplicate sputum microscopy, chest radiography 
and symptomatology fail to detect a large proportion of HIV-associated pulmonary 
tuberculosis cases 152. In particular, patients who have CD4 counts <200 cells/μL or more 
advanced stages of HIV-infection, have a greater risk of sputum microscopy-negative 
tuberculosis 153 and atypical chest radiographs 6,154.  This is important for patient morbidity 
and because smear-negative tuberculosis contributes to tuberculosis transmission 18. The data 
reported here characterized this problem and demonstrated that a single sputum culture with 
MODS was a more reliable screening strategy for hospitalized HIV-infected patients.  
Our study also supports the use of targeted culture-based screening in combination 
with sputum smear microscopy and clinical symptoms in HIV-positive patients. The 
microbiological performance of the MODS technique has been well-defined in comparison 
with traditional egg-based culture and automated tests 148,149,155. This study expands on these 
findings by documenting that most HIV-positive patients with pulmonary tuberculosis can be 
identified when MODS is used with sputum smear microscopy, and that screening with 
MODS was almost as effective when targeted only towards sputum microscopy-negative 
patients with cough and constitutional symptoms at the time of hospital admission.  
We also found that screening HIV-positive hospital admissions for tuberculosis 
without culture misclassified the majority of patients with pulmonary tuberculosis as being 
free from disease. These results reveal that in addition to facilitating early case detection and 
administration of appropriate treatment of tuberculosis disease, rapid, sensitive tuberculosis 
diagnostics also have potential importance in ‘ruling-out’ tuberculosis disease so that HIV-
positive patients may safely receive isoniazid preventive therapy.  
Although the sample size for our current study was small, drug resistance was 
common and without rapid drug-susceptibility testing, most patients with drug-resistant 
tuberculosis in our study would have received inappropriate empiric tuberculosis treatment. 
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Moreover, because most drug resistance was not associated with recognized risk factors for 
drug-resistant tuberculosis, targeted screening for drug-susceptibility status would have been 
of limited benefit. In settings with a high prevalence of drug-resistant tuberculosis, universal 
MODS testing of both sputum smear positive and negative patients with clinical suspicion 
for tuberculosis may be the most appropriate screening strategy needed in order to provide 
early appropriate drug therapy. 
One limitation to the current study is that detection of extra-pulmonary tuberculosis 
using MODS was not investigated. While extra-pulmonary tuberculosis is associated with a 
very low risk of transmission, it still causes morbidity and mortality 156,157. A study in 2002 
by Corey et al. 158, characterizing the natural history of untreated HIV-infection among 
patients in Lima, Peru found that 40% of AIDS patients had tuberculosis. Although our study 
identified 19% of AIDS patients with TB, this is likely due to the fact that we were only 
looking for pulmonary TB rather than extrapulmonary TB (a more common form of TB 
among AIDS patients). 
An additional limitation is that given the number of smear-negative culture-positive 
patients is small, our screening results may require further validation in a second, 
independent dataset or study before clinical recommendations can be confidently made.  
In conclusion, this research demonstrates that active pulmonary tuberculosis was 
common among hospitalized HIV-infected patients and was usually missed by screening 
based on smear microscopy, chest radiography and clinical symptoms. Screening sputum 
microscopy-negative patients with MODS identified the great majority of pulmonary 
tuberculosis allowing early potentially curative therapy. Targeted MODS screening to only 
those patients with symptoms consistent with tuberculosis had similar sensitivity and greater 
efficiency. Screening HIV-positive hospital patients with MODS has the potential to reduce 
TB-related morbidity, mortality and nosocomial tuberculosis transmission.  
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6.6. Figures & Tables 
 
Table 6.1.   Utility of clinical symptoms when screening for pulmonary tuberculosis 
among all hospitalized HIV-infected patients and those who are sputum smear 
microscopy-negative 
 
 
Figure 6.1.  Diagnostic algorithms for screening pulmonary tuberculosis among 
hospitalized HIV-infected patients using MODS 
 
Figure 6.2.   Sensitivity, specificity and proportion of patients who completed screening 
process on same day, for each screening strategy used to detect pulmonary 
tuberculosis 
 
Figure 6.3.  Percentage of HIV-positive patients screened with MODS using each strategy, 
by hospital prevalence of pulmonary tuberculosis 
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Figure 6.2. Sensitivity, specificity and proportion of patients who completed screening 
process on same day, for each screening strategy used to detect pulmonary tuberculosis 
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Figure 6.3. Percentage of HIV-positive patients screened with MODS using each 
strategy, by hospital prevalence of pulmonary tuberculosis*  
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* Universal MODS screening assumed that all patients would be tested using MODS. 
Targeted MODS screening assumed that sputum microscopy had a sensitivity of 39% (95%CI: 22 to 59) and a 
specificity of 100% (95%CI: 98 to 100), and cough among sputum microscopy-negative patients had a sensitivity of 
94% (95%CI: 90 to 98) and a specificity of 44% (95%CI: 36 to 52). 
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CHAPTER 7.  
 Critical Concentrations for detecting drug-susceptibility 
status of Mycobacterium tuberculosis using the Microscopic 
Observation Drug Susceptibility Assay: 
 A laboratory-based study 
 
Technology Development 
As previously mentioned, MODS can be used to detect both culture and drug-susceptibility status of 
tuberculosis. While its diagnostic efficiency for identifying rifampicin and isoniazid resistance is 
superior, for other first line drugs its validity remains sub-optimal. In this final study, we aimed to 
improve the diagnostic validity of MODS for phenotypic detection of ethambutol and streptomycin 
drug resistance, particularly in its low-grade resistant form (also known as “intermediate” drug 
susceptibility status). 
 
 
7.1. Study Summary 
Background: The MODS assay is a rapid method for diagnosis and drug-susceptibility 
testing of Mycobacterium. tuberculosis. The validity of MODS for ethambutol and 
streptomycin drug-susceptibility testing has been poor relative to other first-line drugs such 
as rifampicin and isoniazid. This study aimed to improve its validity by defining the optimal 
critical concentration needed for detecting drug resistance. Methods: We tested 48 pre-
frozen sputum samples using the MODS method with concurrent serial 1:2 dilutions of 
ethambutol and streptomycin solutions in standard 7H9 broth. Drug concentrations ranged 
from 20 to 0.3625 µg/mL for ethambutol, and 8.0 to 0.125 µg/mL for streptomycin. Plates 
were incubated at 37ºC. M. tuberculosis growth was observed by light microscopy. 
Reference standard drug-susceptibility testing was conducted using the Tetrazolium 
Microplate Assay. Results: We found that the optimal critical concentrations for defining 
drug resistance in MODS were 5.0 μg/mL for ethambutol (Sensitivity: 80%, Specificity: 
88%) and 1.0 μg/mL for streptomycin (Sensitivity: 87%, Specificity: 50%). The Minimum 
Inhibitory Concentration for 50% of isolates (MIC50) using MODS was 1.68 μg/mL for 
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ethambutol and 2.16 μg/mL for streptomycin. The Minimum Inhibitory Concentration for 
90% of isolates using MODS (MIC90) was 8.25 μg/mL for ethambutol and 8.85 μg/mL for 
streptomycin. Conclusion: The accuracy of ethambutol and streptomycin drug-susceptibility 
testing in MODS was improved by changing currently used drug concentrations. 
 
7.2. Background 
Mycobacterium tuberculosis remains one of the leading causes of infectious diseases 
worldwide 1. Bacteriological confirmation and administration of appropriate drug-therapy 
remain the most important determinants for treatment success.  
Most standardized treatment regimens include ethambutol and/or streptomycin during 
the initial months of drug therapy 159. Although the mechanisms of drug action for 
streptomycin remain unclear, ethambutol appears to inhibit growth by blocking the synthesis 
of arainogalactan on the cellular wall of M. tuberculosis 160. About 60 percent of ethambutol 
resistant isolates share a common alteration in the embB306 codon 161. However, genetic 
mutations in embB306 do not appear to confer the same classical properties of drug-
resistance found with other drugs 160. M. tuberculosis isolates with the embB306 mutation 
have an increased ability to be transmitted, are more likely to share cross-resistance to other 
drugs such as rifampicin and isoniazid, and usually have a Minimum Inhibitory 
Concentration greater than 16 μg/mL for ethambutol 160. Differentiating between phenotypic 
and genotypic resistance to streptomycin and ethambutol may thus be necessary when testing 
patients for drug-susceptibility status 162.  
Culture-based testing is often limited by the length of time needed to obtain drug-
susceptibility results 24. Cumulative evidence suggests that the Microscopic Observation 
Drug Susceptibility (MODS) assay may be one potential candidate for meeting these goals. 
Based on the principles that M. tuberculosis can be cultured more quickly in liquid rather 
than solid media; and that culture growth of M. tuberculosis can be detected more rapidly 
using a light microscope instead of with the naked eye, several studies have shown a high 
correlation and a shorter turn-around time for detecting isoniazid and rifampicin resistance 
using MODS than reference-standard culture-based techniques 60,61,63,64,163. Despite these 
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promising findings, the diagnostic validity of MODS for ethambutol and streptomycin has 
been limited, with results often being attributed to sampling errors and a tendency to overcall 
drug resistance 163.  
This study aimed to improve the diagnostic validity of MODS for detecting 
ethambutol and streptomycin resistance by defining for the first time the optimal critical 
concentrations needed to phenotypically differentiate between drug resistant and drug-
susceptible samples of M. tuberculosis. 
 
7.3. Materials and Methods (please refer to Appendix 6) 
 
7.3.1. Preparation of Mycobacterium tuberculosis isolates: 
 Sputum samples were tested for smear status using Ziehl-Neelson Smear Stain, then 
decontaminated using the NaOH-NALC method 164 and cultured in Middlebrook 7H9 broth 
(Difco, Detroit, Mich.). Reference standard drug-susceptibility status was conducted using 
previously described methods for the Tetrazolium Microplate Assay (TEMA) 102. Drug 
susceptibility status for an isolate was characterized with reference standard MIC’s using two 
different approaches. For the first method of categorization, isolates were classified 
dichotomously (i.e., drug-susceptible or drug-resistant). A sample was drug resistant if the 
TEMA Minimum Inhibitory Concentration (MIC) was greater than 5.0 μg/mL for 
ethambutol, and 2.0 μg/mL for streptomycin 102. For the second categorization approach, 
isolates were classified into three levels (i.e., susceptible, intermediate, resistant) using the 
TEMA MIC breakpoints listed in Table 7.1. Unused portions of the samples were then stored 
at –20oC. Culture-positive samples were selected for our study from this lot, and retested 
using TEMA.  
 
7.3.2. Preparation of 7h9 broth: 
 2.95 g of Middlebrook 7h9 broth base (Difco, Detroit, Mich.) was dissolved in a solution of 
1.35 mL glycerol, 0.625 g Bacto casitone and 450 mL deionized water. 7h9 broth was 
autoclaved for 15 minutes at 121 to 124ºC, and then cooled to room temperature. One 
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SELECTATAB (Mast Group Ltd., Bootle, UK) and 50mL of OADC were added to the 
broth. To verify sterility, the broth was then incubated at 37ºC for 48 hours. Broth was stored 
at 6 to 8ºC until day of use. 
   
7.3.3. Preparation of antibiotic solutions:  
Ethambutol and streptomycin were obtained from Sigma-Aldrich Chemical Co. (St Louis, 
MO, USA). Two antibiotic stock solutions were prepared by dissolving 5.00 mg of 
ethambutol in 2.5 mL of sterile distilled water; and 5.00 mg of streptomycin in 6.2 mL of 
sterile distilled water. Solutions were filtered through an aqueous solvent filter (pore size: 0.2 
μm; Fisher Scientific, Pittsburgh, PA), and then stored at -20ºC. On the day of use, antibiotic 
starting solutions were made by diluting 15 μL of defrosted stock solution in 1485 μL of 
7h9GC-OADC broth. The final drug concentrations were 20 μg/mL for ethambutol, and 8 
μg/mL for streptomycin. 
 
7.3.4. Inoculation of microplates:  
240 µL of antibiotic stock solution were pipetted into the first row of a 96-well microplate. 
120 µL of 7h9 broth was then pipetted into each remaining well. Figure 7.1 illustrates how 
antibiotic starting solutions were diluted using six concurrent serial 1:2 dilutions of 
ethambutol and streptomycin solutions. Final drug concentrations ranged from 20 to 0.3625 
µg/mL for ethambutol, and 8.0 to 0.125 µg/mL for streptomycin. The last row of microwells 
was used as drug-free control wells. Stored sputum samples were defrosted on ice, and re-
cultured by adding 20 μL of sample to each broth-containing microwell. In order to avoid 
drying, inoculated wells were sealed using scotch-tape. Microplates were then placed in 
ziplock bags and incubated at 37ºC.  
 
7.3.5. Identification of colonies using the MODS method.  
Starting on the fifth day of incubation, control wells were examined for M. tuberculosis 
growth using an inverted light microscope at 40x magnification, every three to four days. On 
the first day that at least ten colonies were observed in the control well or day 21 (whichever 
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came first), the numbers of colonies in each drug-containing well were counted (i.e., First 
Colony Count). Microplates were then re-incubated until day 40, when the numbers of 
colonies in each well were counted again (i.e., Second Colony Count) (please refer to 
Appendix 9). Minimum Inhibitory Concentration was defined as the lowest drug-
concentration that inhibited visible tuberculosis growth.  
 
7.3.6. Determination of critical concentrations.  
Sensitivity, specificity, Youden’s Index and test efficiency measures were calculated for each 
drug concentration using data from the first colony count using previously described formula 
151,165. Differences in proportions were compared using McNemar’s χ2 test. Receiver 
Operating Curves (ROC) were constructed by plotting 1-specificity on the x-axis and 
sensitivity on the y-axis. Area under the ROC curve was then estimated using the trapezoidal 
method. Drug concentrations that inhibited 50 percent (MIC50) and 90 percent (MIC90) of 
samples were calculated for each drug. Optimal drug-concentration breakpoints for detecting 
drug-resistance in M. tuberculosis (i.e., drug-susceptible versus drug-resistant) were selected 
based on the maximum Youden’s Index and test efficiency measures. In order to maximize 
the test efficiency of MODS for detecting samples with intermediate levels of drug-
resistance, we selected a second drug-concentration that had the highest sensitivity across a 
range of drug concentrations and a specificity greater than 0. Amount of growth observed in 
a critical concentration well was calculated by dividing the number of colonies observed in 
the drug-containing well by the number of colonies observed in the control well. 
 
7.4. Results and Discussion 
Forty-eight clinical isolates of M. tuberculosis were used to evaluate susceptibility testing 
towards antimicrobials using MODS. At the beginning of the experiment, we noted that the 
prevalence of ethambutol resistance was relatively rare in Peru, occurring in about two 
percent of M. tuberculosis samples collected in 2006 34. In order to ensure that isolates with a 
wide range of ethambutol and streptomycin MIC’s were tested, previously processed sputum 
samples rather than newly collected sputum samples were used. Thirty-two of the samples 
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(67%) were resistant to streptomycin and 24 (50%) were resistant to ethambutol. Table 7.1 
shows the grades of drug resistance for these isolates. 
Of the 96 “control” wells that were inoculated (48 control wells per drug), 2 (2%) 
wells were dry and 4 (4%) wells were contaminated. This supports previous studies on 
MODS which showed contamination rates between 0 and 2%. 61,163 Although 17 of the 48 
clinical isolates (35%) used failed to grow in both ethambutol and streptomycin control 
wells, culture rates did not differ between samples concentrated 1:1 and 1:100 (χ2: 0.82, 
p=0.32); by grade of smear status (z=1.41, p=0.157); or by grade of drug-resistance for 
ethambutol (z=1.41, p=0.16) or streptomycin (z=0.71, p=0.48). To validate the use of 
previously processed samples, isolates were re-tested using TEMA. Classification of drug-
susceptibility status remained the same using original and re-cultured TEMA MIC’s for all 
but two samples per drug. These discordant results may be explained by the fact that the 
MIC’s for these isolates occurred just at the breakpoint used to classify samples as drug-
resistant or not.   
Table 7.3 displays the diagnostic validity of MODS using different critical 
concentrations. The MODS MIC50 was 1.68 μg/mL for ethambutol and 2.16 μg/mL for 
streptomycin, while the MODS MIC90 was 8.25 μg/mL for ethambutol and 8.85 μg/mL for 
streptomycin. Area under the ROC curve was 0.68 [95% CI: 0.21 to 0.96] for streptomycin 
and 0.87 [95% CI: 0.23 to 1.0] for ethambutol.  
The currently recommended antimicrobial concentrations for testing drug-
susceptibility status with MODS are 2.50 μg/mL for ethambutol and 2.00 μg/mL for 
streptomycin 63,64,163. Table 7.3 shows that in our experiment, the optimal drug concentration 
for detecting ethambutol and streptomycin drug-resistance using MODS was 5.0 μg/mL and 
1.0 μg/mL, respectively. For ethambutol, a change to these new critical concentrations from 
the currently recommended standards resulted in a 13% [95% CI: 2 to 38] increase in 
specificity while the sensitivity remained unchanged. For streptomycin, the change resulted 
in a 27% [95% CI: 8 to 55] increase in sensitivity and a 12% [95% CI: 0 to 53] decline in 
specificity. Although the critical concentrations for both ethambutol and streptomycin 
increased by two-fold when the incubation period was extended from 21 days (i.e., first 
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colony count) to 40 days (i.e., second colony count), cut-offs remained the same regardless of 
whether the original or re-cultured TEMA MIC’s were used as reference standards. 
The median number of colonies observed in critical concentration wells that were 
inoculated with isolates resistant to streptomycin and ethambutol resistant were 7 colonies 
[IQR: 2 – 20] and 8 colonies [IQR: 2 – 10], respectively. Figure 7.2 illustrates the number of 
colonies observed in wells containing these new critical concentrations by grade of resistance 
for the isolate being tested. For culture-positive control wells, the median number of colonies 
observed were 18 colonies [IQR: 10 – 30] at the first count, and 500 colonies [IQR: 200 – 
800] at the second count. 
Figure 7.3 shows that the test efficiency of MODS using these new critical 
concentrations was lowest for M. tuberculosis isolates with intermediate levels of drug 
resistance. Identifying these patients early on is vitally important since amplification of drug-
resistance in M. tuberculosis is more common among partially resistant strains rather than 
fully susceptible strains 109. Additionally, misdiagnosing drug-resistant tuberculosis may 
have a greater impact on the clinical effectiveness of tuberculosis treatment than 
misdiagnosing fully susceptible tuberculosis as drug resistant.  
Considering these observations, we evaluated whether the use of two critical 
concentration wells rather than one would increase the test efficiency of MODS for detecting 
M. tuberculosis with intermediate levels of drug-resistance. Figure 7.3 shows that for 
ethambutol while the test efficiency for detecting drug-susceptible samples dropped by 33%  
[95% CI: 10 to 65], it increased by 33% [95% CI: 1 to 91] for isolates with intermediate 
levels of drug resistance, and 25% [95% CI: 1 to 81] for isolates with high grade drug 
resistance. For streptomycin, there appeared to be little benefit for including two critical 
concentration wells rather than one, since all isolates were classified as resistant. However, 
further validation with larger sample sizes may be needed. 
One criticism of MODS has been the biohazard risk in using liquid culture. Our study 
minimized this danger by using standard laboratory equipment such as biological safety 
cabinets, centrifuge safety caps, sealed rotors, plastic screw-lid vials and inserting plates into 
ziplock bags. Sealing each microplate well with adhesive tape also avoided having to 
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reculture samples if an inoculated plate fell during sample processing. More importantly, all 
lab workers involved in this experiment were trained and experienced in handling M. 
tuberculosis samples (i.e., significant factors when reducing the overall risk of lab-associated 
infections) 166. 
It should be noted that using currently recommended drug concentrations, the 
sensitivity of MODS in our study was superior than previously published studies which 
showed a sensitivity of 42 to 65% for ethambutol resistance and a sensitivity of 44 to 50% 
for streptomycin resistance 64,163. Similarly, the median time to culture-positivity for isolates 
in control wells were 14 days [Interquartile range (IQR): 13 to 21 days] or twice as long as 
previously reported studies on MODS 60,61,63,64. Both of these observations raise the question 
as to whether freezing samples may inhibit the growth of fast growing strains of M. 
tuberculosis. streptomycin and ethambutol are used as sterilizing agents against semi-
dormant strains of M. tuberculosis during the early stages of anti-tubercular treatment 
regimens, thus critical concentrations selected for this type of mycobacteria would be valid 
167. However, future studies evaluating the diagnostic validity of MODS and treatment 
outcome at the second month of treatment (i.e., proxy of semi-dormant strains) may be 
needed to evaluate MODS for detecting rifampicin resistance. 
Similarly, we do not believe that the use of stored samples will influence the validity 
of our study findings. Logistical difficulties and a lack of diagnostic facilities in rural settings 
can often delay testing of sputum samples 168,169. While refrigeration can be used to maintain 
the longevity of samples, about 50% of samples die during the first 8 weeks of storage after 
which the viability of samples stabilizes 170,171. As illustrated in our study, there is little 
evidence to show that storage of samples may influence levels of drug-resistance. However, 
the samples we tested were likely more virulent since the strains most apt to survive storage 
are those with the greatest fitness 136. 
In conclusion, this study showed that the accuracy of ethambutol and streptomycin 
drug-susceptibility testing in MODS was improved by changing currently used drug 
concentrations. Additionally, detection of isolates with intermediate levels of ethambutol 
resistance could be improved by including two critical concentration wells rather than one. 
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7.5. Tables and Figures  
 
 
Table 7.1. Growth characteristics of M. tuberculosis isolates used to validate the 
Microscopic Observation Drug Susceptibility assay 
 
Table 7.2.  Dataset regarding drug-susceptibility results from patients with pulmonary 
tuberculosis who provided more than one sputum sample in study 
 
Table 7.3. Diagnostic validity of the Microscopic Observation Drug Susceptibility 
assay for detecting Mycobacterium tuberculosis resistant to streptomycin 
and ethambutol, by level of drug concentration added to broth. 
 
 
 
Figure 7.1.  Layout of 96-well microplate used for the Microscopic Observation Drug 
Susceptibility assay. 
 
Figure 7.2.  Amount of growth observed using the Microscopic Observation Drug 
Susceptibility assay at the optimal drug concentration, by grade of drug 
resistance for the sample being tested. 
 
Figure 7.3.  Test efficiency of the Microscopic Observation Drug Susceptibility Assay 
for detecting ethambutol and streptomycin resistance in Mycobacterium 
tuberculosis using one versus two critical concentration wells. 
 
 
 
 
 
 
 
 
89
 
  T
A
B
L
E
 7
.1
.  
G
ro
w
th
 c
ha
ra
ct
er
is
tic
s o
f M
yc
ob
ac
te
riu
m
  t
ub
er
cu
lo
sis
 is
ol
at
es
 u
se
d 
to
 v
al
id
at
e 
th
e 
M
ic
ro
sc
op
ic
 O
bs
er
va
tio
n 
D
ru
g 
Su
sc
ep
tib
ili
ty
 a
ss
ay
 
 
Le
ve
l o
f  
Dr
ug
  
Re
sis
ta
nc
e 
Ra
ng
e o
f 
MA
BA
 
Mi
ni
m
um
 
In
hi
bi
to
ry
 
Co
nc
en
tra
tio
n 
Nu
m
be
r o
f  
Sa
m
pl
es
 
Te
st
ed
 
Nu
m
be
r o
f  
Sa
m
pl
es
  
Gr
ow
n 
in
 C
on
tro
l W
ell
* 
%
 o
f  
Sa
m
pl
es
 G
ro
wn
 
in
 C
on
tro
l W
ell
*  
(9
5%
 C
I) 
Et
ha
mb
uto
l 
 
 
 
 
 
Su
sc
ep
tib
le 
Le
ss
 th
an
 4.
0 
18
 
12
 
67
 (4
1 –
 87
) 
 
Int
er
me
dia
te 
4.0
 to
 8.
0 
11
 
4 
36
 (1
1 –
 69
) 
 
Re
sis
tan
t 
Gr
ea
ter
 th
an
 8.
0 
18
 
5 
28
 (1
0 –
 55
) 
St
re
pto
my
cin
 
 
 
 
 
 
Su
sc
ep
tib
le 
Le
ss
 th
an
 2.
0 
3 
1 
33
 (1
 – 
91
) 
 
Int
er
me
dia
te 
2.0
 to
 4.
0 
27
 
15
 
56
 (3
5 –
 75
) 
 
Re
sis
tan
t 
Gr
ea
ter
 th
an
 4.
0 
17
 
7 
41
 (1
8 –
 67
) 
CI
: C
on
fid
en
ce
 In
ter
va
l 
 * C
on
tro
l w
ell
s d
id 
no
t c
on
tai
n a
nti
bio
tic
s. 
90 
 
 
Table 7.2.  Dataset regarding drug-susceptibility results from patients with pulmonary 
tuberculosis who provided more than one sputum sample in study* 
 
 
 
Patient 
Sample 
Number 
Sputum 
Microscopy 
MABA 
Ethambutol Streptomycin 
 
1 1 2 S I 
 2 3 S I 
 
2 1 3 I R 
 2 3 I I 
 
3 1 2 R S 
 2 2 R I 
 
4 1 2 R I 
 2 2 R I 
 
5 1 2 R I 
 2 3 R I 
 3 3 R I 
 4 2 R I 
 
6 1 2 R I 
 2 3 R I 
 3 3 R R 
 4 3 R R 
 
7 1 3 S I 
 2 2 I I 
 
8 1 3 S I 
 2 3 S I 
 3 3 S I 
 4 3 S R 
 5 3 S R 
 6 3 S R 
 7 3 I R 
 
9 1 3 I R 
 2 1 R R 
 3 1 R R 
 
10 1 2 I I 
 2 2 I R 
 3 3 R I 
 4 1 R I 
   
Number  of Discordant Results  per Patient 
 Susceptible & Resistant 0 0 
 Susceptible & Intermediate 2 1 
 Intermediate & Resistant 2 4 
 Total 4 5 
*Isolates from a patient  was graded with the following levels of drug resistance: 
S=Susceptible; I=Intermediate; R=Resistant 
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FIGURE 7.1. Layout of 96-well microplate used for the Microscopic Observation Drug 
Susceptibility assay. Each plate was used to test 6 samples (columns 1, 3, 5, 7, 9 and 11) per drug. 
7h9 broth was pipetted into all wells within these columns. Antibiotic starting solutions were then 
placed in row b and double-diluted in the direction of the arrow (). Each grey circle () represents 
a control well with 7h9 broth that was free of antibiotic.  
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FIGURE 7.3.  Test efficiency of the Microscopic Observation Drug Susceptibility Assay 
for detecting ethambutol and streptomycin resistance in Mycobacterium tuberculosis 
using one versus two critical concentration wells. Drug resistance was determined for 
ethambutol using one drug concentration well (5.00 μg/mL) or two drug concentration wells (5.00 
μg/mL or 1.25 μg/mL); and for streptomycin using one drug concentration well (1.00 μg/mL) or two 
drug concentration wells (1.00 μg/mL or 0.50 μg/mL). An isolate was classified as drug-resistant if 
M. tuberculosis grew in at least one drug-containing well. 
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CHAPTER 8.  
General Discussion 
 
8.1. Overview of Results 
The research undertaken in this thesis represented an effort to: [1] build a knowledge 
foundation regarding the underlying factors associated with outbreaks of MDR-TB among 
HIV/AIDS patients; [2] use this knowledge framework to develop health measures for 
controlling pulmonary tuberculosis among HIV/AIDS patients; and [3] in an effort to better 
implement these health measures, refine existing culture-based diagnostics for M. 
tuberculosis. 
To increase understanding of the role of AIDS on the worldwide epidemic of MDR-
TB, we conducted a longitudinal study within AIDS and non-AIDS populations who were 
receiving DOTS treatment for pulmonary tuberculosis in Lima, Peru, and who were 
undergoing an ongoing epidemic of MDR-TB. Our study revealed that while DOTS for drug-
susceptible tuberculosis was protective against amplification of drug-resistance in pan 
susceptible strains of M. tuberculosis, it did not confer protection against infection with a 
different MDR-TB strain. Our molecular epidemiological analysis also revealed that while 
one particular strain of MDR-TB occurred more frequently among patients in the AIDS 
cohort (i.e., Lam9), the risk of superinfection with this epidemic strain of MDR-TB was the 
same for both groups of patients after adjusting for baseline prevalence of circulating strains. 
Considering this evidence, our study then focused on answering the question: Why did AIDS 
patients in Lima, Peru have such a high incidence of MDR-TB to begin with? 
An analysis of patients from both the AIDS and non-AIDS cohorts revealed that those 
infected with the epidemic clone of MDR-TB were more likely to present with diarrhea as 
compared to patients infected with other MDR-TB clones. One explanation for these results 
is that infection with another enteric pathogen may have increased patients’ susceptibility to 
superinfection with an MDR-TB strain during DOTS. Humoral immune responses against 
diarrhea-associated parasites are thought to favor infection with M. tuberculosis, making 
HIV-infected patients particularly vulnerable to disease. Similarly, the gastrointestinal tract 
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has long been recognized as a major site of opportunistic infections among HIV-infected 
patients, due in part to the tract being a major site of HIV replication, causing in turn the 
lamina propia of the stomach to undergo extensive depletion of CD4 cells 110,127.  
In order to understand the role of gastrointestinal-related factors and infection with M. 
tuberculosis, the next study in this thesis involved characterizing the prevalence and factors 
associated with shedding mycobacteria in the stool of AIDS patients 45 110 110,128.  Our study 
revealed that among AIDS patients in the early stages of pulmonary tuberculosis, about 45% 
shed viable mycobacteria in stool. In contrast, 77% of AIDS patients who were in the later 
stages of pulmonary tuberculosis shed mycobacteria. The higher rate of shedding among late 
stage pulmonary tuberculosis patients may have been due in part to smear positive disease 
being more common in this group. However, AIDS patients are also more likely to 
experience disseminated disease in the later stages of pulmonary tuberculosis 6. We also 
noted that hospitalization during the previous two years was a protective factor against 
shedding, after adjusting for history of tuberculosis. These results suggest that 
gastrointestinal colonization with M. tuberculosis is less common among AIDS patients who 
had previously received medical care for another opportunistic infection.  
The next stage of this thesis aimed to develop screening strategies for pulmonary 
tuberculosis among AIDS patients. Our study findings revealed that pulmonary tuberculosis 
was common among hospitalized AIDS patients but frequently misdiagnosed using currently 
recommended diagnostic algorithms. Using blanket culture-based screening with the 
Microscopic Observation Drug Susceptibility Assay, we were able to identify almost all 
cases of pulmonary tuberculosis. Moreover, MODS was equally effective when targeted to 
patients clinically suspicious for tuberculosis. Although we used MODS to detect both the 
presence and drug susceptibility status of tuberculosis among these patients, for other first 
line drugs such as ethambutol and streptomycin the results have been suboptimal. 
In our final study, we refined the ability of MODS for detecting resistance to 
ethambutol and streptomycin by evaluating its diagnostic validity across a range of drug-
concentrations. We found that by modifying currently used drug concentrations we could 
increase the test efficiency for ethambutol and streptomycin by 10% and 13% respectively. 
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Despite these promising results, the test efficiency of MODS was lowest for strains with low 
grade drug resistance. This form of drug resistance may pose the greatest challenge for 
clinical management of tuberculosis since patients with low grade resistance are more likely 
to develop high grade resistance as compared to patients with completely susceptible strains 
of M. tuberculosis 109. Our study revealed that the diagnostic efficiency of MODS for 
detecting low grade drug resistance could be improved by using two drug-concentration 
wells instead of one. 
 
8.2. General Implications 
These results have several implications, both at the clinical and public health level. First, our 
studies highlight the need for careful administration of tuberculosis prophylaxis. This 
includes accurately ruling out all forms of tuberculosis (not just pulmonary tuberculosis) 
before administering mono-drug prophylaxis, and providing patient support and observation 
at the same level as that found in DOTS programs. For HIV-infected patients, detection of 
tuberculosis is particularly important due to their increased risk of presenting with extra-
pulmonary tuberculosis and their tendency to exhibit atypical symptoms depending on the 
extent of immunosuppression 6. Considering the high risk of drug complications among HIV 
infected patients and the need to adequately prevent infection with tuberculosis during 
prophylaxis, patient support may also be important for increasing patient compliance.  
 Second, our results showed that while DOTS can adequately protect against the 
development of drug-resistant tuberculosis, it does not confer protection against 
superinfection with drug-resistant strains. This may be particularly problematic in hospital 
settings where HIV-infected patients may be placed in wards regardless of whether they are 
infected with TB or not 10,94. There is thus a need to identify and isolate patients with drug-
resistant tuberculosis early on.  
Third, our study illustrated how AIDS patients with pulmonary tuberculosis had more 
strains in common than non-AIDS patients, despite residing in more geographically dispersed 
regions. We attributed this paradoxical difference in strain distribution to socialization 
practices. At the time that data collection for this study took place, HIV infection was 
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extremely low in the general population of Peru and largely restricted to marginalized 
populations such as injection drug users, homosexual men and those involved in prostitution 
118. The socialization practices that initially led to HIV infection may have thus been the 
same practices as those that led to TB infection. In light of these findings, contact 
investigations should be based not only on household contacts but also on social contacts.  
Fourth, our study demonstrated how current standards of diagnosis in resource-
constrained settings (i.e., sputum smear stain microscopy, chest radiographs or clinical 
manifestations) may be of limited clinical utility among HIV-infected individuals. These 
results highlight the importance of culture-based diagnosis and drug-susceptibility testing of 
tuberculosis. Similarly, identification of tuberculosis with low grade drug resistance is 
essential since these strains may pose the greatest challenge for clinical management of 
tuberculosis. Amplification of drug-resistance is more likely to occur among samples with 
low-grade resistance rather than fully susceptible strains. Until now, the main focus for 
selecting diagnostic cutoffs for drug-susceptibility tests has been to differentiate between 
isolates with extremely high or extremely low MIC’s. For the MODS assay, this problem 
may be minimized by using two drug-concentration wells instead of one.  
Finally, our study revealed that hospitalization during the previous two years was a 
protective factor against shedding mycobacteria in stool, even after adjusting for previous 
history of tuberculosis. Although the reasons for this link are unclear, hospitalization and 
previous residence in a prison or shelter may be acting as markers for access to health care in 
this deprived population for which health care is not free of charge. Our results thus highlight 
the indirect effect that general health care among HIV-infected patients can have on the 
development of tuberculosis. They also support recent suggestions to better integrate public 
health programs for tuberculosis and HIV in order to control HIV-associated tuberculosis 81.  
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8.3. Comments on Study Design and Limitations 
 
8.3.1. Sample Size 
The greatest limitation of this thesis was sample size. On several occasions, we used an exact 
logistic regression model or Fisher’s exact test in order to adjust in our analysis for cells with 
less than five patients.  
 For our first study (i.e., evaluating the role of AIDS in an epidemic of MDR-TB), we 
estimate that in order to detect a 50% increase in risk among MDR-TB patients infected with 
Lam9, we would have needed to enroll 279 Lam9 MDR-TB cases and a total of 1116 MDR-
TB patients using an alpha level of 0.05, a beta level of 0.80 and using a ratio of three 
controls per case.  
 Recruiting this number of subjects would probably not have been very feasible, 
considering the rarity of MDR-TB in Peru. Although in 2006, the Peruvian Ministry of 
Health identified 96 patients or 5.3% of all new tuberculosis cases as having MDR-TB in all 
of Peru 34, this number has declined steadily since the full introduction of the national MDR-
TB program in 2005. Our study identified 100 MDR-TB patients over a 6 year span, from 
which 23 were infected with the Lam9 strain of MDR-TB. As compared to other previously 
published studies on MDR-TB and AIDS, this number represented a relatively large sample 
size 109,120,121. A further complicating factor when selecting accrual periods for molecular 
epidemiological studies is that the molecular dynamics of M. tuberculosis may change over 
the span of one or two decades, particularly if tuberculosis cases represent recent rather than 
reactivated forms of disease. 
 Sample size also remained a key issue in our second study (i.e., stool shedding of 
mycobacteria). We estimate that the lowest odds ratio that our models could detect was ≤0.60 
or ≥4.6 using an alpha of 0.05 and a beta of 0.80. As previously mentioned, the literature 
regarding stool shedding among tuberculosis patients is limited. Aside from the fact that we 
were using a secondary dataset, anticipating sufficient sample sizes would have been very 
difficult to predict, given the information available to us at the time, regarding stool 
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shedding. It is also interesting to note that in order to identify 30 patients with early stage 
tuberculosis, 473 respiratory symptomatic patients needed to be screened.   
 In an effort to increase statistical power using secondary datasets, we analyzed data 
for this thesis using the 90 and 95 percent confidence intervals. Figure 8.1 illustrates how, in 
our first study, by decreasing the alpha by 0.05, statistical power could be increased by 10 to 
15% depending on the strength of the association. Still, our analysis may have failed to detect 
certain true associations, and thus should only be used to rule in rather than rule out potential 
factors.  
 Aside from statistical power issues, sample size also influenced the type of samples 
we used in our final study (i.e., defining optimal critical concentrations for MODS). For this 
experiment, we needed to test samples with a wide range of MIC’s using samples from a 
population with a relatively low prevalence of ethambutol resistance. In 2006, only 36 
patients or 2% of all tuberculosis cases in Peru were resistant to ethambutol 34. In an effort to 
avoid long accrual periods and maximize the range of MIC’s tested, we used stored rather 
than fresh samples in our study. 
 
Figure 8.1. Curves illustrating the statistical power in study #1 for identifying factors 
associated with infection with the epidemic clone of MDR-TB, by strength of the 
association of the factor.   
  
 
*Our study included a total sample size of 91 subjects with a ratio of 3 controls per case. 
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8.3.2. External Validity 
An essential element to consider when reviewing our results is the issue of generalizability. 
The first half of this thesis revealed that epidemic clones of MDR-TB were associated with 
diarrhea and that shedding of mycobacteria in stool was common among AIDS patients, 
particularly among those reporting loss of appetite and lower BMI’s. Although these findings 
suggest greater gastrointestinal involvement for HIV-associated tuberculosis than previously 
thought, our results should not be generalized beyond AIDS patients. As previously 
mentioned, the gastrointestinal tract remains the most common site of opportunistic 
infections among HIV-infected individuals 45 110. This is partially attributable to the 
gastrointestinal tract being a major site of HIV replication resulting, in turn, in a depletion of 
CD4 cells within the lamina propia of the stomach 110,128. In this context, the pathophysiology 
of tuberculosis may differ between HIV-positive and HIV-negative individuals. 
Aside from gastrointestinal differences, we also found in our first study that an 
epidemic of MDR-TB among AIDS patients was due to one particular strain of M. 
tuberculosis (i.e., Lam9). It is difficult to determine whether this outbreak represented a 
strain effect that could occur under similar conditions in other settings. However, our 
molecular analysis revealed that while multiple clones of Lam9 strains of MDR-TB were 
circulating among AIDS patients, only one was associated with an epidemic of MDR-TB. 
Similarly, other epidemics in Argentina and the United States were caused by W and M 
strains, and not Lam9 89 119.  
External validity also remained an issue in our third study. We identified different 
tuberculosis screening strategies using MODS among hospitalized AIDS patients in a low 
HIV burden setting. In Peru, HIV-seropositivity rates are estimated at less than 1% 136. It is 
unclear whether these results would be generalizable to high HIV-burden settings such as 
Africa where the prevalence of HIV infection can reach as high as 30%.  
   
 
 
 
102 
 
 
8.3.3. Internal Validity 
Several issues were raised in this thesis in regards to internal validity. Our study showed that 
shedding was more common among patients in the later stages of pulmonary tuberculosis. 
One explanation for these results is that smear-positive disease was more common among 
patients in the later stages of pulmonary tuberculosis. Our regression analysis of factors 
associated with shedding also revealed that cough and loss of appetite were useful predictors 
for identifying patients who may be shedding. Although our study screened AIDS patients 
for respiratory symptoms during the previous 15 days, loss of appetite was not included in 
our screening criteria. The prevalence of shedding among patients in this cohort may have 
thus been underestimated. 
 Recall bias can often occur when an individual reports information only after learning 
of their diagnosis. It can be particularly problematic when cases recall to a greater extent than 
controls, information normally not considered important. While this thesis relieved heavily 
on interview-derived information, we do not believe that recall bias was an issue since all of 
the study participants were unaware of their drug-susceptibility status, strain/clone of 
infection, and stool shedding status at the time of patient interview. It should also be noted 
that while diarrhea was included as one exposure factor in our first study, our original 
questionnaire actually asked study participants whether they had one of seven underlying 
medical conditions (i.e., diabetes, diarrhea, cardiopathy, renal disease, cancer, liver disease 
and/or other). It was only during the analysis, that it became apparent that several patients 
had diarrhea, while rather than diarrhea alone, thus further reducing the possibility of 
selection or recall bias.  
 
8.4. Future Research Directions 
The findings from the first half of this thesis suggest that future research must be undertaken 
in order to better clarify the association between HIV-associated tuberculosis and 
gastrointestinal related factors such as diarrhea. The link between these two factors was 
somewhat surprising and was only discovered when patients were asked regarding seven 
different underlying medical conditions. Although the mechanisms underlying this 
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association are purely speculative, an increased susceptibility for acquiring MDR-TB 
following infection with other diarrhea associated diseases might partially explain our results. 
As previously mentioned, humoral immune responses against diarrhea-associated parasites 
are thought to favor infection with M. tuberculosis and HIV 111 112 113. In light of these 
observations, future epidemiological studies on tuberculosis and diarrhea might be designed 
to examine the role that infection with different diarrhea-associated parasites has on the risk 
of infection and the development of active tuberculosis. This area of research may be 
particularly relevant for HIV-infected children in the developing world, where the incidence 
of childhood diarrhea may be high. 
Conversely, the identification of mycobacteria in stool may have important 
implications for developing tuberculosis diagnostics. For individuals who exhibit non-
productive cough, invasive procedures such as nasal-gastric aspiration or hypertonic 
solutions may be needed to induce or extract sputum 142. Examination of stool rather than 
sputum could limit the use of such invasive procedures, thus minimizing patient discomfort 
while facilitating diagnosis. 
Finally, our study illustrated through paradoxical differences in strain distribution, 
how transmission of tuberculosis may be more closely linked to social interactions rather 
than geographical location, per se. One of the questions raised from this finding is how the 
social structures that exist for a society or a group of individuals enable transmission to 
occur. This body of research could be based on different aspects of social network theory 172, 
which focuses on elucidating the characteristic patterns of social relationships or links 
between different persons in a social network (or community), rather than the individuals 
themselves 173. For transmission dynamics, elucidating these links could be achieved by 
combining data from social and molecular networks of disease transmission. 
 For example, by identifying the degree of centrality or position of a person within a 
social network, one may be able to identify whether certain individuals are more “capable” of 
spreading tuberculosis as compared to others 173. This analysis would enable public health 
practitioners to distinguish between a person who is capable of spreading an airborne 
communicable disease to an entire community (e.g. a school teacher), as compared to one 
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who, given their small social network, is only capable of transmitting a disease to their close 
family or friends. Using this information, public health specialists may then be able to better 
target tuberculosis interventions such as treatment or case-contact investigations, in order to 
avoid future disease transmission. 
 Concomitantly, social network theory could be used to identify thresholds for the 
transmission of certain microorganisms. Also known as “tipping points” 173, social network 
analysis may be used to analyze how easily M. tuberculosis is spread throughout a network. 
Social network theory may also help in elucidating the density of connections within a social 
group, through the use of network segmentation. This information could be particularly 
useful when evaluating and comparing the biological fitness of resistant versus non-resistant 
bacteria spread during a social interaction. 
 Unlike other models, the advantage of social network theory lies in its ability to 
contextualize social interaction dynamics. Although research in this area has largely been 
dedicated to describing the structure of social organizations, several conceptual elements of 
this theory may provide significant insight into how tuberculosis is transmitted. 
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CHAPTER 9.  
Overall Conclusions and Recommendations 
 
The following conclusions and recommendations were derived on the basis of the study 
findings and discussion of the results: 
 
Study #1: 
Most AIDS patients with drug-susceptible pulmonary tuberculosis who acquired MDR-TB 
during DOTS were infected by a different strain of M. tuberculosis rather than by 
amplification of drug-resistance (i.e., secondary drug-resistance). While this strain was more 
common among AIDS patients, its risk of infectivity did not differ between AIDS and non-
AIDS patients, suggesting that another factor may have contributed to the strain’s high 
prevalence among AIDS patients. Diarrhea was associated with risk of infection with this 
clone. Previous prophylaxis was also a useful factor for “ruling in” infection with this 
epidemic clone. Finally, our study provided further evidence regarding the role of social 
networks on TB transmission, particularly among socially marginalized populations. 
Recommendations: 
 Public health strategies to control for TB and HIV should be better integrated. This 
includes providing HAART and taking a more holistic approach to patient care. 
 Patients with DR-TB need to be identified and isolated quickly in order to avoid 
nosocomial transmission of DR-TB in hospitals and/or DOTS clinics. For patients, 
receiving DOTS this can include isolating them in a separate ward or treating them at 
different times of day (e.g., patients with DS-TB in the morning, those with MDR-TB 
in the afternoon). 
 Contact investigations for tuberculosis should not only include household contacts but 
also social contacts, especially when controlling the disease among socially 
marginalized populations. 
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 In settings with a high burden of MDR-TB, treatment for latent tuberculosis should 
include two drugs rather than one (e.g., isoniazid + rifampicin or isoniazid + 
pyrazinamide). Before receiving prophylaxis, patients should be properly screened for 
all forms of tuberculosis (i.e., pulmonary and extra-pulmonary tuberculosis). Finally, 
prophylaxis and treatment for latent tuberculosis should be administered with the 
same level of patient support as DOTS.  
 
Study #2:  
Shedding of mycobacteria in stool was common among AIDS patients in the later stages of 
pulmonary tuberculosis, but rarely occurred in the absence of pulmonary tuberculosis. 
Although, type of cough (productive or not) did not influence the risk of shedding, patients 
were more likely to shed mycobacteria in stool if they had smear-positive disease. Cough and 
loss of appetite were useful predictors for identifying patients who might be shedding. Past 
hospitalization was also a protective factor against colonization. 
Recommendations: 
 Strategies aimed at preventing airborne transmission of tuberculosis (e.g., ultraviolet 
lights) may not be sufficient for preventing nosocomial transmission of the disease. 
Efforts should be made to ensure that patients with pulmonary TB are quickly 
diagnosed and properly treated.  
 Although current guidelines for recommend that patients with otherwise unexplained 
productive cough lasting 2-3 weeks be screened for TB 17, consideration should be 
given in extending these guidelines to include those with unproductive forms of 
cough.  
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Study #3:  
Active pulmonary tuberculosis was common among hospitalized AIDS patients but was 
usually missed by screening based on smear microscopy, chest radiography and clinical 
symptoms. Blanket screening with MODS identified the majority of these patients. However, 
targeted screening based on symptoms had similar sensitivity and greater efficiency. 
Recommendations: 
 MODS (or at the very least some sort of culture or molecular-based method of 
detection) should be used in addition to standard criteria used for TB diagnosis, when 
screening hospitalized HIV-infected patients in developing countries. 
 
Study #4: 
Our study showed that the validity of MODS for ethambutol and streptomycin drug-
susceptibility testing could be improved by modifying currently used drug concentrations to 
5.0 μg/mL for ethambutol and 1.0 μg/mL for streptomycin. Similarly, detection of isolates 
with intermediate levels of drug-resistance could be improved by using two critical 
concentration wells rather than one. 
Recommendations: 
 Identification of patients with low-grade drug-resistance should be considered since 
they are more likely than patients with drug-susceptible tuberculosis to develop high 
grade drug resistance due to genetic amplification. 
 Critical concentrations used in MODS to identify resistance of M. tuberculosis to 
ethambutol and streptomycin should be modified.  
 Two critical concentration wells rather than one should be used in order to detect low-
grade drug-resistance in M. tuberculosis. 
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Variables included in Chapter 4 analysis 
(Role of AIDS during an ongoing outbreak of MDR-TB) 
 
Variable Definition Scale 
Outcomes 
Pulmonary tuberculosis 
 
Isolation of culture positive Mycobacterium 
tuberculosis from sputum 
[Yes, No] 
 
 
 
Dichotomous Drug-Resistant 
tuberculosis 
(includes mono-
resistance to rifampicin or 
isonizanid, and multi-drug 
resistance to both 
rifampicin and isoniazid) 
Mycobacterium tuberculosis that is 
resistant to either rifampicin or isoniazid 
[Yes, No] 
Strain of M. tuberculosis The lineage of M. tuberculosis as characterized by 
spoligotype 
 
Categorical 
(multiple strains) Clone of M. tuberculosis An isolate of M. tuberculosis descending from a 
common precursor strain as characterized by 
RFLP 
Independent Variables 
Sputum smear status Presence of acid fast bacilli in sputum 
[0-, 1+, 2++, 3+++] 
Dichotomous 
(smear 
positive/negative) or 
Quartiles 
Age Age in years at the time of diagnosis Continuous 
Sex Male, Female  
 
 
 
 
 
 
Dichotomous 
HIV-infection Tested positive for HIV [Yes, No] 
Underweight A body mass index less than 18.5 kg/m2  
[Yes, No] 
History of TB Previous diagnosis of TB 
[Yes, No/Not known] 
Contact with tuberculosis Known contact with a tuberculosis patient  
during the previous two years  
[Yes, No] 
Past hospitalization Hospitalized  
during the previous two years 
[Yes, No] 
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Clinical Manifestations 
Cough Persistent, urgent or strong cough that is  
more than just an irritating cough and  
occurs several times during the day 
[Yes, No] 
 
Dichotomous 
Productive Cough Urge to cough or clear throat, accompanied by 
phlegm, saliva, etc. and occurs several times 
during the day 
[Yes, No] 
 
 
 
 
 
 
 
 
Dichotomous 
Fever Body temperature is above 37 ̊C several times in a 
day 
[Yes, No] 
Shortness of breath Sensation of shortness of breath or normal breathing 
which does not provide enough air 
[Yes, No] 
Hemoptysis Same as productive cough but accompanied by blood 
[Yes, No] 
Weight loss Evident loss of weight with no explanation 
[Yes, No] 
Loss of appetite Evident loss of appetite with no explanation 
[Yes, No] 
Night Sweats Recurrent atypical sweating during the night 
[Yes, No] 
Fatigue Tiredness or weakness with no explanation 
[Yes, No] 
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Variables included in Chapter 5 analysis 
(Shedding of mycobacteria in stool of patients with pulmonary tuberculosis) 
 
Variable Definition Scale 
Outcomes 
Pulmonary tuberculosis Isolation of culture positive Mycobacterium 
tuberculosis  
from sputum  
[Yes, No] 
 
 
 
Dichotomous 
Shedding in Stool Isolation of cuture positive mycobacteria  
from stool  
[Yes, No] 
Shedding in Urine Isolation of culture positive mycobacteria  
from urine  
[Yes, No] 
Independent Variables 
Sputum Smear Status 
Presence of acid fast bacilli in sputum  
[0-, 1+, 2++, 3+++] 
Dichotomous 
(smear positive or 
negative) 
or Quartiles 
Age Age in years at the time of diagnosis  
Continuous Body Mass Index (BMI) BMI in kilograms per meters2 
CD4 Count Number of CD4 cells per μL 
Sex Male, Female  
 
 
 
 
 
 
 
Dichotomous 
History of TB Previous diagnosis of TB  
[Yes, no/Not known] 
History of TB prophylaxis Patient previously received prophylaxis  
during the previous year for tuberculosis 
[Yes, No/Not known] 
Antiretroviral Therapy Receiving antiretroviral drugs for HIV  
at the time of diagnosis  
[Yes, No] 
BCG Vaccination Presence of a BCG scar on  
either arm of the patient  
[Yes, No] 
Contact with tuberculosis Known contact with a  
tuberculosis patient during the previous two years  
[Yes, No] 
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Past hospitalization Hospitalized during the previous two years  
[Yes, No] 
Worked and/or lived in 
Prison or shelter 
Worked and/or lived in prison or shelter  
during the past  
[Yes, No] 
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Variables included in Chapter 6 analysis 
(Clinical utility of MODS for screening AIDS patients for pulmonary TB) 
 
Variable Definition Scale 
Outcomes 
Pulmonary tuberculosis 
 
Isolation of culture positive Mycobacterium 
tuberculosis from sputum 
[Yes, No] 
 
 
 
Dichotomous Sputum smear status Presence of acid fast bacilli in sputum 
[0-, 1+, 2++, 3+++] 
Independent Variables 
Cough Persistent, urgent or strong cough that is 
more than just an irritating cough and 
occurs several times during the day 
[Yes, No] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dichotomous 
Productive Cough Urge to cough or clear throat, accompanied by 
phlegm, saliva, etc. and occurs several 
times during the day 
for 15 days or more 
[Yes, No] 
Prolonged Cough Urge to cough or clear throat, accompanied by 
phlegm, saliva, etc. which presents itself 
several times a day 
[Yes, No] 
Fever Body temperature is above 37 ̊C several times in a 
day 
[Yes, No] 
Weight loss Evident loss of weight with no explanation 
[Yes, No] 
Night Sweats Recurrent atypical sweating during the night 
[Yes, No] 
Constitutional symptoms Reported cough with at least 
one constitutional symptom 
(fever, night sweats or weight loss) 
[Yes, No] 
Radiographic 
appearance of TB 
Chest radiograph consistent with tuberculosis 
(e.g., presence of pleural lesions, cavitation, infilitrates 
or hilar enlargement) 
[Yes, No] 
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Appendix 10 
Additional study results on 
stool shedding of Mycobacterium tuberculosis 
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The gastrointestinal tract continues to be the most common site for opportunistic infections among 
HIV-infected individuals (1, 2). The elevated risk of infection is often attributed to the gastrointestinal 
tract being a major site of HIV replication, which causes a depletion in CD4 counts making the 
patient vulnerable to infection (3, 4). Previous studies have shown that almost half of otherwise 
healthy patients with smear-positive cavitary pulmonary tuberculosis are infected by gastrointestinal 
tuberculosis (5). Despite this evidence, there is little research regarding the prevalence of stool 
shedding with Mycobacterium tuberculosis among AIDS patient (6). In this paper, we determined the 
extent of gastrointestinal involvement in pulmonary tuberculosis by examining the prevalence and 
risk factors for stool shedding among AIDS patients. 
Data was collected between March 2002 and January 2004 at the Infectious Disease Clinic of 
the Hospital Dos de Mayo. We examined stool shedding among two groups of AIDS patients at 
different stages in the natural history of tuberculosis. The first group (i.e., patients in early stages of 
pulmonary tuberculosis) was identified by screening 473 consecutively enrolled HIV-infected 
patients who reported coughing during at least one week. Patients with productive or wet cough 
(n=154) were asked to provide two sputum and one stool sample. Sputum samples were collected on 
consecutive days with all samples being collected within a one-week period. Patients with a non-
productive or dry cough (n=319) were asked to provide one sputum and one stool sample on the same 
day. Sputum was induced using a hypertonic saline solution. The second cohort (i.e., patients in 
advanced stages of tuberculosis) consisted of 106 AIDS patients who were already diagnosed with 
tuberculosis (pulmonary or extra pulmonary forms) at the time of study entry; and, who were about to 
commence Directly Observed Therapy Short-Course (DOTS) as part of the Peruvian National 
Tuberculosis Control Program. Patients were interviewed at the start of treatment regarding clinical 
manifestations and asked to provide one sputum and one stool sample at the time of study enrollment 
(day 0), day 1 as well as at month 1, month 2, month 4, month 6 of DOTS treatment, and once at the 
end of treatment. Patients recruited into the early-stage cohort were eligible to participate in the 
advanced-stage cohort if they were recommended for tuberculosis treatment at a later time. None of 
the study participants in either cohort were receiving tuberculosis treatment at the time of study 
enrolment.  
 Sputum samples were tested for smear status using Auramine Smear Microscopy; culture 
status using Lowenstein-Jensen and Middlebrook 7h9 Broth (Difco, Detroit, Mich.); and drug-
susceptibility status using the Microplate Alamar Blue Assay (MABA). Stool samples were tested for 
smear status using Auramine Smear Microscopy; and then cultured using Lowenstein-Jensen, 
Middlebrook 7h9 Broth and Middlebrook 7h10 Agar (Difco, Detroit, Mich.). Stool samples were only 
tested for drug-susceptibility status using MABA if the matching sputum sample from a patient was 
culture-negative. All culture-positive sputum and stool samples were tested for the presence of 
Mycobacterium tuberculosis using a hemi-nested PCR assay targeting the IS6110 insertion element. 
Patients had pulmonary tuberculosis if they produced at least one sputum sample that was culture-
positive for M. tuberculosis.  
 We found that from the 458 patients who provided sputum and stool samples at study entry, 
4.3% (20/473) of early-stage cohort patients and 41% (43/106) of late stage cohort patients tested 
positive for pulmonary tuberculosis. Among patients recruited into the early-stage cohort, 31% 
(48/154) with wet cough and 4.4% (14/319) with dry cough had pulmonary tuberculosis.  Stool 
shedding only occurred in the presence of pulmonary tuberculosis, even when patients were 
diagnosed with extra-pulmonary tuberculosis. 50% (31/62) pulmonary tuberculosis patients shed 
culture-positive M. tuberculosis in stool. Of the 29 pulmonary tuberculosis patients who provided 
sputum samples on consecutive days, 19 (65%) shed M. tuberculosis in stool on both days. Of the 33 
patients with later stage pulmonary tuberculosis who were followed-up during stool shedding, 28 
(85%) stopped shedding by the first month of DOTS. The remaining 5 (15%) patients who continued 
lxxxi 
 
 
to shed were infected by rifampicin-resistant tuberculosis, and thus may have been failing to respond 
to treatment. Stool shedding was more common among pulmonary tuberculosis patients with a dry 
cough [Adjusted Odds Ratio (aOR): 16.4, 95% Confidence Interval (CI): 1.5 – 177]. Stool shedding 
was not influenced by stage of disease [aOR: 8.4, 95% CI: 0.8 – 91], but shedding increased by grade 
of sputum smear status (χ2 test for trend=8.91, p=0.03). This trend remained in our inferential-based 
analysis after adjusting for age, sex, stage of disease and type of cough [Adjusted Odds Ratio: 2.48, 
95% Confidence Interval: 1.2 to 5.3]. Table 1 also shows that shedding was disproportionately greater 
for patients with an AFB grade 3+++ sputum smear.  
 
Table 1. Factors associated with pulmonary tuberculosis patients shedding Mycobacterium 
tuberculosis in stool  
`  AFB= Acid Fast Bacilli 
 
 
 
 
 
 
 
 
 
 
Characteristic 
Number of Pulmonary Tuberculosis 
Patients 
 
 
 
Crude Odds Ratio 
 
Adjusted Odds Ratio 
(95% Confidence Interval) 
No stool shedding 
n=31 
Shedding  
in stool 
n=31 
Age 
 Less than 25 years 
 25 to 29 years 
 30 to 34 years 
 35 years or more 
 
4 
6 
12 
9 
 
3 
13 
9 
6 
 
- 
2.89 
1.0 
0.89 
 
- 
3.05 (0.3 – 28) 
1.03 (0.1 – 9.2) 
0.90 (0.1 – 8.6) 
Sex 
 Male 
 Female 
 
26 
5 
 
25 
6 
 
- 
1.25 
 
- 
1.75 (0.3 – 12) 
AFB Grade of Sputum Smear 
 0 
 1+ 
 2++ 
 3+++ 
 
 
10 
11 
4 
6 
 
 
4 
7 
3 
17 
 
 
- 
1.59 
1.87 
7.08 
 
 
- 
1.41 (0.2 – 10) 
2.60 (0.2 – 32) 
8.59 (1.1 – 69) 
Type of Cough 
 Wet 
 Dry 
 
25 
6 
 
23 
8 
 
- 
1.45 
 
- 
16.4 (1.5 – 177) 
Stage of disease 
 Early 
 Late 
 
14 
17 
 
6 
25 
 
- 
3.43 
 
- 
8.4 (0.8 – 91) 
